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Mammalian cystatins are tight-binding, reversible inhibitors of potentially destructive
cysteine proteases, both endogenous and exogenous.  The N-terminal region  residues,
Ile2 and especially Pro3, and the second binding  loop residues, Leu73 and to some
extent Pro74, of the family 1 cystatin, cystatin A, were  shown to be essential for
effective inhibition of papain and cathepsins L and B. Both regions were found to act
in  endopeptidase  inhibition  primarily by anchoring the enzymes in long-lived
complexes with the inhibitor. However, in inhibition of the exopeptidase, cathepsin B,
the N-terminal region also contributes to the high association rate.
As previously shown for cystatin C, stopped-flow kinetics demonstrated a two-step
mechanism of cystatin A binding to cathepsin B, with a conformational  change in the
second, rate-limiting  step. In contrast, binding of cystatins A  and C to a cathepsin B
variant with an increased mobility of the occluding loop that blocks the  active-site
cleft occurred in an apparent one-step reaction. The second step of cathepsin B binding
by cystatins  was therefore concluded  to involve displacement of the occluding  loop.
Cystatin C was shown to be a much better displacer of this loop than cystatin A.
New  effective and specific inhibitors of  cysteine proteases  were  engineered by
grafting  individual binding regions of more  potent cystatins into cystatin A.
Introduction of motifs from the second  binding loops of cystatins B  or C into the
corresponding  loop of cystatin A increased the affinity for  papain by ~10-fold.
Moreover, replacement of the N-terminal region of cystatin A by that of cystatin C
resulted in the affinity for cathepsin B being increased ~15-fold, to a level higher than
that of any natural cystatin  known. The  latter chimeric inhibitor  was as effective as
cystatin C in displacing the occluding loop of cathepsin B, the rate of this step being
increased by ~100-fold. The  N-terminal  region of a cystatin was  thus concluded to
promote occluding loop displacement by appropriately positioning the binding  loops
of the inhibitor entering the active-site cleft of cathepsin B.
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Introduction
Proteases, also termed peptidases, are crucial for normal functioning of all cells
and organisms. They are enzymes that catalyze the hydrolysis of peptide bonds in
proteins and peptides. Depending on the location of the cleavage site, proteases are
divided into endopeptidases (or proteinases) and exopeptidases. Endopeptidases
cleave internal peptide bonds in target polypeptide chains, whereas exopeptidases,
comprising amino- and carboxypeptidases, hydrolyze bonds near either the N- or
C-terminus of polypeptides, respectively. Based on the specific chemical groups
responsible for catalysis, proteases are classified into five major types: the serine,
cysteine, aspartic, threonine and metallo-peptidases (Rawlings & Barrett, 1999).
There are also  proteases for which the catalytic mechanism remains to be
determined; these are classified as proteases of unknown type.
Proteases have a key role in general  protein  turnover and also have  other vital
functions, exerted via processing of proteins by limited cleavage. Their activity is
strictly regulated at different levels, since uncontrolled proteolysis would damage
the finely tuned biological machinery  of cells and tissues and lead to
pathophysiological states and eventual death of the organism. Inhibition of
proteases by protein inhibitors represent one of the most important mechanisms of
regulating protease activity.
Cysteine  proteases have been found in all kind of organisms, from viruses,
bacteria and protozoa to plants and vertebrates. This thesis briefly reviews different
aspects concerning the classification, structures, functions and inhibition of
cysteine proteases. It focuses on cystatins, protein inhibitors of papain-like
cysteine proteases. Cystatins are  believed to protect an organism from the
potentially  harmful  activity of endogenous target proteases  as well as from
proteases  released by infectious  virus,  bacteria  and parasites. The mode of
inhibition of papain-like cysteine proteases by mammalian cystatins is highlighted
in both Previous and Present investigations.
Previous investigations
Cysteine proteases of the papain family
Classification
In the recently developed MEROPS  database, proteases of the major types are
classified  into clans and families according to their evolutionary relationship,
reflected by structural similarities in the "peptidase unit", i.e.  in the part of the
enzyme  responsible for peptide bond hydrolysis (Barrett & Rawlings, 2001;
Rawlings & Barrett, 1993, 1999, 2000; Rawlings et al., 2002). Proteases with
statistically significant similarities in amino-acid sequences  are  grouped  into
families. Clans are  formed by related families, which are  suggested to have
evolved from a common ancestor in light of similar tertiary and/or secondary
structures, as well as identical catalytic motifs and limited similarities around the10
catalytic residues (Barrett & Rawlings, 2001). Cysteine proteases  are  subdivided
into eight clans: CA, CD, CE, CF, CH, CK, PA and PB (Barrett & Rawlings,
2001). A common mode of action of members of the largest clan, CA, is reflected
by the presence of the catalytic triad Cys/His/Asn(Asp) in these proteases. Papain-
like  cysteine proteases, inhibition of which is the main subject of this thesis,
comprise the C1 family of this clan. This family includes plant proteases (such as
papain, chymopapain, caricain, bromelain, actinidin, ficin and aleurain),  cysteine
proteases from  Trypanosoma,  Leishmania,  Schistosoma,  Giardia,  Fasciola  and
other parasites, bleomycin hydrolase from various organisms and a number of
mammalian lysosomal cathepsins. The origin of the C1 family may predate the
eukaryote/prokaryote divergence or, at the latest, the ancestor of the papain family
could be a digestive protease in vacuoles of an archeprotozoa, which then diverged
into proteases in plant vacuoles and mammalian lysosomes (Barrett et al., 1986b;
Berti & Storer, 1995).
Catalytic activity and substrate binding
In proteases of the C1 family, Cys25, His159, Asn175 and also Gln19 (in papain
numbering)  are  highly  conserved  residues, directly involved in peptide bond
hydrolysis. In general, a protease active site is comprised of such catalytically
active residues as well as of residues contacting the bound substrate. The substrate
binding area can be subdivided into a number of so called  binding  pockets or
subsites, each contacting a single amino-acid residue of the bound substrate (Fig.
1) (Schechter & Berger, 1967).  In papain, seven binding  pockets were  initially
suggested to accommodate seven subsequent residues of a substrate,  four S
subsites binding substrate residues N-terminal to the scissile peptide bond (P
residues), and three S' subsites binding substrate residues C-terminal to this bond
(P' residues). This nomenclature for substrate binding subsites has long been used
for description of the subsites in other papain-like cysteine proteases. However, a
more  recent  analysis of available three-dimensional structures of papain-like
proteases in complex with a substrate analogue and of kinetic data has prompted a
revision of this nomenclature (Turk et al., 1998). Only three binding sites in the
different proteases, S2, S1 and S1', were shown to interact with the corresponding
substrate residues via both main-chain and side-chain  atoms,  whereas the
interactions between residues of the S3 or S2' subsites and the substrate involved
only side-chain contacts. As no evidence for the existence of common S4 and S3'
subsites in different papain-like proteases was found, the use of the less precise
term "binding area"  was suggested for the regions interacting with  substrate
residues beyond P2 and P2' (Turk et al., 1998, 2000).
The substrate of a papain-like cysteine protease binds along the active-site cleft of
the  enzyme in a rather extended conformation and in such a manner that the
peptide bond to be hydrolyzed comes in close proximity to the sulfhydryl group
of the catalytic Cys25, which acts as a nucleophile attacking the carbonyl carbon
of the scissile bond. The imidazolium ring of the neighboring His159 accepts a
proton from the nucleophile and simultaneously acts as a proton donor for the
nitrogen atom of the scissile bond. Asn175 contributes to a proper orientation of
this imidazolium ring, whereas the side chain of Gln19 participates in stabilizing
an intermediate acyl-enzyme  product (Storer & Menard, 1994; Otto &11
Fig. 1. Schematic representation of a peptide substrate bound in the active site of a
papain-like cysteine protease, according to Schechter & Berger  (1967).  Seven
successive amino-acid residues (P4 to P3’) of the substrate  are  suggested to interact
with seven distinct  substrate-binding  subsites  (S4 to S3’) of the protease. The  prime
notation  denotes residues C-terminal of the scissile peptide bond (indicated by an
arrow), which is in close proximity to the catalytic Cys.
Schirmeister, 1997). In the first, acylation, step of the hydrolysis, an acyl-enzyme
is formed, and a peptide with the P1' residue at its N-terminus dissociates from
the active site of the protease. The next, deacylation, step involves a nucleophilic
attack on the acyl-enzyme by a water molecule, which results in dissociation of a
second peptide product with the P1 residue as C-terminus and in the regenerated
protease.
Lysosomal cathepsins
General characterization
Mammalian  proteases  that  are  localized in lysosomes  are in general termed
cathepsins  (Kirschke  et al., 1995; Turk et al., 2002b). A major part of them
belongs to the papain family of cysteine proteases, i.e. cathepsins B, C, H, L, S,
K, O, F, X, V and W. Most papain-like cathepsins are endopeptidases, although
both cathepsins B and H also exhibit endopeptidase activity. Cathepsin B is thus
a carboxypeptidase and cathepsin H an aminopeptidase. Cathepsins C and X are
true exopeptidases, cathepsin C being an aminopeptidase and cathepsin X a
carboxy-mono or -dipeptidase (Turk et al., 2001b). Lysosomal cathepsins are
generally  monomers  with  molecular  masses of ~30 kDa. The only  exception
known is cathepsin C, which is a tetramer of ~200 kDa. Most cathepsins exhibit
an optimum of their activity at a slightly acidic pH and in the presence of reducing
compounds.
Lysosomal cathepsins are  synthesized as inactive precursors  with an N-terminal
extension, comprising a signal sequence  that directs the proteins to the
endoplasmatic reticulum and a propeptide (also called a proregion or prosegment).
The length of the propeptide varies from 38 residues in cathepsin X to 251
residues in cathepsin F (Cygler & Mort, 1997; Groves et al., 1998; Wiederanders,
2000). The propeptide binds into the S and S' binding subsites of the cathepsin in
the  reverse  orientation  relative to that of a substrate, thereby  inactivating the
enzyme. Activation of the proenzyme occurs by cleavage and removal of the
propeptide from the active site with no global conformational rearrangements of
the protein. Besides keeping the proenzyme  inactive, the propeptide has been
shown to be essential for correct folding of the cathepsin and for transport of the
         
 ‘ ‘ ‘      	

 
 
 
‘ 
‘ 
‘ 


12
proenzyme to lysosomes or endosomes. It has also been suggested to contribute to
increased stabilization of the proenzyme at neutral pH (Khan & James, 1998; Turk
et al., 2000). Endopeptidases can be autoactivated in an acidic environment,
whereas  the true exopeptidases, cathepsins C and X, are  activated by other
proteases (Turk et al.,  2001b). The autocatalytic activation is an intermolecular
process, in which one of cathepsin molecules activates another one in a chain-like
reaction (Turk et al., 2000). Lysosomal glycosaminoglycans have been proposed
to promote cathepsin processing in vivo by weakening the interaction between the
propeptide and the active-site cleft (Turk et al., 2000).
On the basis of sequence homology, papain-like cathepsins have been suggested to
be divided into two main subgroups, the cathepsin L- and B-like proteases (Cygler
& Mort, 1997; Turk et al., 2000). The propeptides of  proteases of these two
types  differ  both in size and sequence.  Cathepsins of the first subgroup,
comprising cathepsins L, V, K, S , W, F, and H, have propeptides that are usually
~100 residues long with two highly conserved motifs, ERF(W)NIN  and  GNFD.
The second group comprises cathepsin B variants from different sources with ~60
residues long propeptides lacking the former conserved motif. Cathepsins F and W
have alternatively been proposed to form a separate, third subgroup of cathepsin F-
like proteases with a conserved ERFNAQ-motif in the propeptide (Wiederanders,
2000). Propeptides of the other cathepsins do not show any homology with either
cathepsin L-, B- and F-like proregions or to each other.
Tertiary fold
The high sequence homology of members of the C1 family of cysteine proteases
results in similar tertiary structures (Fig. 2). A polypeptide chain of a typical
endopeptidase of the family is folded into two domains, separated by the  deep
"V"-shaped active-site cleft (Kirschke et al., 1995; Turk et al., 1997, 1998). The
L-domain consists of most of the N-terminal half of the protease polypeptide chain
and has an α-helical structure. The R-domain is formed by the extreme N-terminal
residues and the C-terminal half of the chain and is folded into a β-barrel, covered
at the top and bottom by shorter α-helical motifs. The essential catalytic residues,
Cys25 and His159, are situated on the opposite sides of the cleft in the L- and R-
domains, respectively, on the rim between a shallow, wide part and a narrow, deep
part of the crevice. Residues that form the more open part of the active-site cleft,
comprising the S1 and S2 subsites, are highly conserved in members of the C1
family.
Exopeptidases of the papain family have  the same common fold as
endopeptidases. However, in the former, the access to the substrate binding sites is
restricted by additional structural elements, which determines the exopeptidase
activity of these enzymes. In particular, in cathepsin B an insertion of about 20
residues forms a loop that covers  the top of the active-site cleft and partially
occludes the S2' and S3' substrate binding subsites (Musil et al., 1991; Nägler et
al., 1997). The presence of this loop greatly reduces the endopeptidase activity of
cathepsin B. Moreover, the positively  charged  imidazole side chains of His110
and His111 in the loop can  bind the negatively charged  C-terminal  carboxylic
group of a polypeptide substrate and direct the latter into position for hydrolysis13
Fig. 2. Structural  similarities  between papain-like cysteine proteases, illustrated by a
stereo view of the superposition of  Cα  atom traces of nine members of the papain
family. The structures are shown in the standard view with the R- and L-domains at the
right and left, respectively,  and with the active-site clefts at the top. The  catalytic
Cys25 of papain is marked. The structure distinguished from the others by the presence
of  the loop on top of the active-site cleft is that of cathepsin B. (Reprinted, with
permission,  from Turk et al.  (1998).  Copyright  1998,  Walter de Gruyter & Co,
Berlin–New York.)
of the C-terminal dipeptide, thereby accounting for the dipeptidylcarboxypeptidase
activity of cathepsin B (Musil et al., 1991; Illy et al., 1997).
In cathepsin H, a glycosylated fragment of the propeptide, called the mini-chain, is
attached to the mature enzyme  through a disulfide bond in such a manner  that
three of its residues occupy the S2 and S3 substrate-binding subsites in the active-
site cleft (Guncar et al., 1998; McGrath, 1999). Another part of the active-site cleft
of cathepsin H is partially filled with the carbohydrate rings of the mini-chain. The
negatively  charged  C-terminal  carboxyl  group of the mini-chain has been
suggested to interact with the positively charged  N-terminal  amino group of a
substrate. The mini-chain and part of its carbohydrate chain, together with a short
four-residue  insertion loop in the active-site  cleft,  are  thus  responsible  for the
aminopeptidase activity of cathepsin H that results in cleavage of a single residue
from the N-terminal end of the substrate. Similarly, the active-site cleft in
cathepsins X and C, which are true exopeptidases, is partially occluded by a mini-
loop and a propeptide segment, respectively (Nägler et al., 1999; Klemencic et al.,
2000; Sivaraman et al., 2000; Olsen et al., 2001; Turk et al., 2001a).
Cathepsins in physiological and pathophysiological states
Lysosomal proteases play important roles in terminal degradation of proteins and
generation of amino acids for synthesis of new proteins. Most  papain-like
cathepsins, such as cathepsins B, C, F, H, L, O, and X, are  ubiquitously
expressed.  Therefore, a common role associated with a nonspecific  intracellular
"housekeeping " function, i.e. breakdown of proteins targeted to lysosomes, has
been ascribed to these cathepsins. In support of such a nonspecific role,14
experiments with knock-out of the genes for cathepsins B and L showed that these
two cathepsins are  not essential for normal foetal growth. Cathepsin B- or L-
deficient mice were normal at birth, and no defects in protein  degradation  were
observed  (Deussing  et al., 1998; Nakagawa  et al., 1998; Roth et al., 2000),
indicating that other proteases  could take over most functions of the absent
cathepsins.
In addition to nonspecifically degrading proteins, papain-like cathepsins also
participate in protein processing by limited proteolysis, thereby  regulating many
important physiological processes (Turk et al., 2000, 2001b). In these reactions,
cathepsins may act very specifically. In cathepsin C-deficient mice, the activation
of certain proteases was thus impaired (Pham & Ley, 1999). Furthermore, lack of
cathepsin L in mice resulted in periodic hair loss and epidermal hyperplasmia,
suggesting that cathepsin L is essential for regulation of normal proliferation of
hair follicle epithelial cells and basal keratinocytes of the epidermis (Roth et al.,
2000). Mice deficient in cathepsin L also had impaired processing of the invariant
chain of major histocompatibility complex (MHC) class II molecules in cortical
thymic epithelial cells (Nakagawa  et al.,  1998).  Moreover, cathepsin F was
suggested to be important for this process in macrophages (Shi et al., 2000).
The relatively recent discovery of cathepsins with expression restricted to specific
tissues or cell types has suggested new roles for these proteases (Chapman et al.,
1997a; McGrath, 1999; Buhling et al., 2000; Turk et al., 2000). Thus, cathepsin
S is found predominantly in lymphatic tissues such as spleen, lymph nodes and
peripheral leukocytes, cathepsin K is highly expressed in osteoclasts at sites of
bone resorption, cathepsin V is thymus- and testis-specific and cathepsin W is
predominantly expressed in lymphocytes. Studies with cathepsin S-deficient mice
demonstrated  that  this  protease is specifically required for processing of the
invariant chain in peripheral antigen presenting cells such as macrophages, B-cells
and dendritic cells (Shi et al., 1999; Villadangos et al., 1999). Cathepsin V was
suggested to be responsible for catalysis of the same reaction in human thymic
epithelial cells (Turk et al., 2000). Different cathepsins have thus been shown to
be linked to antigen presentation, possibly acting through different pathways (Turk
et al.,  2002c). Furthermore, cathepsin K was found to be critical for bone
resorption, a part of the dynamic remodeling of bone (Saftig et al., 2000; Turk et
al., 2000). Knockout of the cathepsin K gene in mice thus  caused an impaired
ability of osteoclasts to resorb bone during growth, which led to osteopetrosis, or
increased bone density. In this state, bone demineralization proceeds normally but
not digestion of the bone matrix. Another tissue-specific cathepsin, cathepsin V,
was indicated to be involved in T-cell selection in humans,  whereas a specific
function in T-cell-mediated cytotoxicity was proposed for cathepsin W (Bhandoola
et al., 2000; Turk et al., 2000). A number of novel, tissue-specific cathepsins in
other mammals have also been reported, i.e. rat and mouse cathepsins Q, M, P,
and R, which are primarily expressed in placenta and therefore may play important
roles in implantation and embryonic development (Sol-Church et al., 2002).
Extracellular cathepsins are potentially very destructive. In particular, abnormally
high levels of extracellular  papain-like cathepsins have been observed during
development of various cancer  types and metastasis (Calkins & Sloane, 1995;15
Henskens et al., 1996; Friedrich et al., 1999; Fernandez et al., 2001; Colella et
al., 2002). In cancer progression, such cathepsins are responsible for activation of
other proteases and for degradation of components of the extracellular matrix (Turk
et al., 2000, 2002c). However, intracellular cathepsin B has also been implicated
to  have specific roles in reducing malignancy, in particular by acting as an
execution  protease in tumor cells (Foghsgaard et al., 2001; Szpaderska &
Frankfater,  2001). In agreement,  lysosomal  cathepsins  have been indicated to
participate in apoptosis also under other circomstances (Turk et al., 2000, 2002a).
Lysosomal  cathepsins may also be secreted by other than cancer  cells,  i.e.  by
activated macrophages, osteoclasts and fibroblasts.  Papain-like cathepsins, often
extracellular or extralysosomal,  have  thus  been  linked to development of such
diseases as inflammation, rheumatoid arthritis and ostearthritis, gingivitis,
osteoporosis, asthma, pulmonary emphysema, Alzheimer's disease, multiple
sclerosis,  muscular  dystrophy,  pancreatitis,  myocardial disorders and
glomerulonephritis (Turk et al., 1997, 2000, 2002b).
Genetic defects in cathepsins may cause severe physiological disorders. Mutations
in the human cathepsin K gene that lead to a total loss of enzyme  activity  were
found to be associated with pycnodysostosis, a genetic disorder with an
osteopetrotic phenotype (Saftig et al., 2000), in agreement  with the knock-out
experiments in mice. Moreover, a loss-of-function mutation in the cathepsin C
gene was shown to cause Papillon-Lefevre syndrome, characterized by early-onset
periodontis and palmoplantar keratosis (Toomes et al., 1999).    
Regulation of activity of cathepsins
The activity of lysosomal papain-like cathepsins is regulated in many ways, i.e. at
the gene  translation and expression levels, by localization, by synthesis of the
proteases  as inactive precursors, by posttranslational modifications and by
degradation  (Chapman  et al., 1997b; Turk et al., 1997, 2000). Alternative
splicing of the cathepsins B and L genes has been observed to result in highly
elevated  translation and increased protease stability, as well as in an altered
targeting mechanism and increased secretion. An essential regulating factor of the
proteolytic activity of lysosomal cathepsins is the pH of the environment. Thus,
the decrease in pH occurring during maturation of lysosomes presumably weakens
the interaction between the propeptide and the proenzyme, favoring the activation
process. Furthermore, cathepsins B,  S and L are  indicated to be irreversibly
denaturated in lysosomes towards the end of the maturation process, when pH has
decreased to a value of 3.8. In addition, many cathepsins, viz. cathepsins L, B, H,
K,  V and F, are  unstable at neutral pH and therefore are less  active  outside
lysosomes. Finally, endogenous protein inhibitors are considered to be common
and most important means of regulating the activity of mature cathepsins that have
escaped lysosomes, as well as of exogenous cysteine proteases released by different
infectious microorganisms (Turk et al., 2001b, 2002b).
Protein inhibitors of cysteine proteases of the papain family
Depending on their major physiological function, protein inhibitors of proteases
may be subdivided into emergency  and modulatory inhibitors (Turk  et al.,16
2002b). Protein inhibitors of the first type defend living cells and organisms in
acute cases of occasionally increased proteolysis. They rapidly bind to their target
proteases and inactivate these either irreversibly or for sufficiently long times. Two
kinetic parameters have been suggested as criteria for whether protein inhibitors are
capable of fulfilling this role. These are the delay time, which determines the time
needed for ~99% completion of the binding reaction, and, in the case of reversible
interactions, the stability time, during which an inhibitor—protease complex
remains essentially intact and which is defined as 1/10th of the half life of the
bimolecular complex (Bieth, 1984). Protein inhibitors that act with a delay time
of <1 s and have a stability time of >10 min are regarded as emergency inhibitors.
Normally, inhibitors of this type are localized separately from their target proteases
and  are in molar  excess over the  protease when performing their  protective
function. By contrast, modulatory inhibitors are  colocalized  with their target
proteases  and  regulate  the endogenous activity of the latter at different  levels,
either by irreversible or pseudo-irreversible slow binding of activated  proteases
(delay type) or by rapid binding of these proteases in short-lived complexes (buffer
type). Threshold inhibitors are also modulatory inhibitors that act similarly to the
emergency  inhibitors,  although in lower  physiological  concentrations  compared
with those of the proteases. A change of conditions, such as salt concentration and
pH, or the presence of cofactors can alter the properties of protein inhibitors and
convert them from one type to another.
Cystatins
Cystatins are protein inhibitors of cysteine proteases of the papain family (Barrett,
1986; Turk & Bode, 1991; Turk et al., 1997). Cystatins inactivate target proteases
reversibly and competitively by indirect blockage of the catalytic centers of these
enzymes, thereby preventing substrate docking and cleavage. In general, cystatins
bind  target  proteases  with  rate  constants as high as 10
4  to 10
7 M
-1.s
-1  and
dissociation constants in the nM to fM range. They form very stable bimolecular
complexes with the proteases, keeping these inactive for hours and weeks. Hence,
cystatins can function as either emergency or threshold  inhibitors. Cystatins are
widely distributed in animals, plants and protozoa, both intracellularly and
extracellularly,  which indicates an important physiological role (Barrett, 1986;
Turk & Bode, 1991; Irvine et al., 1992). They are believed to protect cells and
organisms from uncontrolled activity of endogenous cysteine proteases  released
from lysosomes of dying or deceased cells. In addition, cystatins have been shown
to be potent inhibitors of cysteine proteases used by microorganisms and parasites
for invading host cells and entire organisms.
Cystatins  are  evolutionarily  related  proteins with a conserved  physiological
function. The cystatin superfamily comprises proteins with diverse  primary
structures, sizes and distributions. In particular, members of this superfamily can
be  one- or multidomain proteins, with or without disulfides, as well as
glycosylated or nonglycosylated. Nevertheless, statistical analysis of their amino-
acid sequences suggests that cystatins originate from a common ancestor protein
with no disulfide bonds and that a precursor containing such bonds appeared about
1000 million years ago (Rawlings & Barrett, 1990). Further evolution of cystatins
occurred, presumably by insertion and deletion of genetic material in small blocks17
and also later by gene  duplication. Proteins of the cystatin superfamily are
traditionally subdivided according to their sequence similarities into three major
families (Barrett et al., 1986a). Originally, closely related proteins, diverging by
less than a half of their amino-acid residues, were grouped  into these individual
families (Barrett, 1986; Rawlings & Barrett, 1990). However, later discovered
cystatins  have  also  been added to these families, despite a sequence  similarity
between some new family members and the old ones of substantially lower than
50%. Major characteristics for the classification of cystatins have instead become
the size of the polypeptide chain and the presence or absence of internal disulfides.
This simplification has led to uncertainties regarding  the assignment of some
cystatins to a particular family, and revision of the classification established to
date, as well as introduction of new cystatin families or subfamilies, therefore
appears to be necessary.
Family 1 cystatins
Members of this family, also called  stefins,  are  the smallest in the cystatin
superfamily, having a molecular mass of ~11 kDa. The single polypeptide chain of
these proteins, consisting of ~100 residues, is folded into one domain. Family 1
cystatins lack both disulfide bridges and carbohydrates, thus representing the most
primitive form of cystatins (Turk & Bode, 1991). This family includes cystatins
A and B, found in different mammals: man (Machleidt et al., 1983; Green et al.,
1984; Ritonja et al., 1985; Abrahamson et al.,  1986),  cow (Turk et al.,  1992,
1995a), rat (Takio et al., 1983, 1984; Takeda et al., 1985), sheep (Ritonja et al.,
1996), pig (Lenarcic et al., 1993, 1996) and mouse (Tsui et al., 1993), as well as
bovine stefin C (Turk et al., 1993) and pig stefin D (Lenarcic  et al., 1996).
Alignment of sequences of family 1 cystatins reveals three evolutionarily  highly
conserved regions, viz. a Gly residue in the N-terminal region, a QVVAG segment
in the middle of the polypeptide chain and a LP pair in the C-terminal part of the
chain (Fig. 3).
Family 1 cystatins are  located  primarily intracellularly, in the cytosol (Turk &
Bode, 1991), although they have  also  been detected in low  concentrations in
different extracellular fluids (Abrahamson et al., 1986). Cystatins A and B are the
most studied members of the family. Cystatin A is found predominantly in
various epithelial cells and in polymorphonuclear leukocytes (Brzin et al., 1983;
Green et al., 1984; Järvinen et al., 1987), whereas cystatin B is widespread among
different  cells and tissues (Davies & Barrett, 1984;  Katunuma & Kominami,
1985; Barrett, et al., 1986b; Lenarcic et al., 1986; Henskens et al., 1996). These
differences in distribution may reflect different physiological roles of the two
cystatins. Cystatin A is often considered as a first-line guardian against cysteine
proteases released by infectious microorganisms and parasites, whereas cystatin B
presumable has a general protective function.
Family 2 cystatins
Family 2 members, uniformly termed cystatins, are also single-chain, one-domain
proteins, although somewhat, ~2 kDa, larger  than the family 1 inhibitors. The
polypeptide chains of cystatins of family 2 are ~120 residues long and contain two
characteristic disulfide bridges, at conserved positions in the C-terminal part of the18
molecule (residues 71–81 and 95–115 in chicken cystatin numbering) (Rawlings
& Barrett, 1990) (Fig. 3). In addition to the four cysteines, three other conserved
regions are characteristic for members of cystatin family 2. A Gly residue in the N-
terminal region, a QxVxG sequence in the middle of the chain and a PW dipeptide
in the C-terminal part of a molecule are present in all cystatins of this family (Fig.
3). Most cystatins known are nonglycosylated, although mouse and rat cystatin C
and also cystatins E/M and F are glycoproteins (Esnard et al., 1990; Solem et al.,
1990; Ni et al., 1997, 1998). Family 2 cystatins are  synthesized as preproteins
with a signal peptide and are  present  predominantly in extracellular  fluids,
although some have  also  been  found  intracellularly  (Abrahamson  et al., 1986;
Halfon  et al., 1998; Abrahamson, 1994; Nathanson et al., 2002). The family
includes mammalian cystatins: cystatin C of several different species (Poulik  et
al., 1981; Grubb & Löfberg, 1982; Hirado et al., 1985; Esnard et al., 1988;
Solem  et al., 1990; Tu et al., 1990), cystatin D (Freije et al., 1991, 1993),
cystatin E/M (Ni et al., 1997; Sotiropoulou et al., 1997; Zeeuwen et al., 2001),
cystatin F/leukocystatin (Halfon  et al., 1998; Ni et al., 1998; Morita et al.,
1999), cystatins S, SA and SN (Isemura  et al., 1984, 1986, 1987), and also
chicken egg-white cystatin (Turk et al., 1983).
Fig. 3. Amino-acid sequences of representatives of families 1 and 2 of the cystatin
superfamily.  CA, human  cystatin A; CB,  human  cystatin B; CC,  human  cystatin C;
EWC, chicken egg-white cystatin. Protein sequences were taken from the SWISS-PROT
database (accession codes CYTA_HUMAN,  CYTB_HUMAN, CYTC_HUMAN and
CYT_CHICK, respectively) and aligned within each family. Signal peptides of family 2
cystatins are not shown. The motifs conserved within each family are in bold.
Family 1
CA  MIPGGLSEAK PATPEIQEIV DKVKPQLEEK TNETYGKLEA 40
CB  MMCGAPSATQ PATAETQHIA DQVRSQLEEK ENKKFPVFKA
CA  VQYKTQVVAG TNYYIKVRAG DNKYMHLKVF KSLPGQNEDL 80
CB  VSFKSQVVAG TNYFIKVHVG DEDFVHLRVF QSLPHENKPL
CA  VLTGYQVDKN KDDELTGF
CB  TLSNYQTNKA KHDELTYF
Family 2
CC  SSPGKPPRLV GGPMDASVEE EGVRRALDFA VGEYNKASND  40
EWC   SEDRSRLL GAPVPVDEND EGLQRALQFA MAEYNRASND
CC  MYHSRALQVV RARKQIVAGV NYFLDVELGR TTCTKTQPNL  80
EWC KYSSRVVRVI SAKRQLVSGI KYILQVEIGR TTCPKSSGDL
CC  DNCPFHDQPH LKRKAFCSFQ IYAVPWQGTM TLSKSTCQDA 120
EWC QSCEFHDEPE MAKYTTCTFV VYSIPWLNQI KLLESKCQ19
The recently reported cystatins E/M and F have only ~30% sequence identity with
other cystatins of family 2. Nevertheless, they have been included in this family,
mainly on the basis of their size and the presence of two  conserved  disulfide
bonds, as well as the other evolutionarily conserved  regions of the primary
structure that are typical for family 2 cystatins. Cystatin F differs from the other
family members by the presence of one additional disulfide bridge in the N-
terminal part of the molecule. Chicken cystatin and cystatins C, E/M and F,
besides being inhibitors of cysteine proteases of family C1, like all cystatins, also
inhibit an entirely different  enzyme,  mammalian legumain, of family C13 of
cysteine proteases (Chen et al., 1997; Alvarez-Fernandez et al., 1999).
The best studied representatives of family 2 cystatins are  chicken  cystatin and
human cystatin C, the latter being the most abundant of the inhibitors of the
cystatin  superfamily  in all human body fluids examined, with the highest
concentration in seminal plasma and cerebrospinal fluid (Abrahamson et al., 1986;
Olafsson et al., 1988; Abrahamson, 1994). The broad distribution of this protein
implies its essential role in protection of the organism against exogenous and
endogenous, occasionally released, cysteine proteases. Cystatins of the S-type are
found predominantly in saliva but also in tears, urine and seminal plasma (Isemura
et al., 1984; Abrahamson et al., 1986).
The distribution of cystatins D, E and F has not been investigated as extensively
as that of cystatin C. Cystatin D has been found in saliva and tears and cystatin E
in small amounts in urine (Freije et al., 1993; Ni et al., 1997). Cystatin F has
been detected in low concentrations in blood and shown to be secreted in trace
amounts by B cells and in significant amounts by T cells in culture (Ni et al.,
1998). Most information available concerns the expression pattern of the genes for
these cystatins obtained by DNA and RNA techniques. The cystatin D gene has
been shown to be expressed only in the parotid glands (Freije et al., 1991). Data
on expression of the gene for cystatin E/M are inconsistent. Different groups have
reported diverse expression patterns of this cystatin, with expression being highest
in liver, ovary and pancreas (Ni et al., 1997), in primary breast cancer tumors with
no expression in liver or brain (Sotiropoulou et al.,  1997) or restricted to
epithelial cells and sweat glands (Zeeuwen et al., 2001). Expression of the cystatin
F gene has been detected in a number of tissues, the highest levels being found in
peripheral blood leukocytes and spleen (Ni et al., 1998) and also in hematopoietic
cells and some human cancer cell lines (Halfon et al., 1998; Morita et al., 1999).   
Family 3 cystatins
Family 3, or the kininogen family, comprises the largest and most complex
inhibitors of the cystatin superfamily, with molecular masses of ~50 or ~70–80
kDa (Barrett et al., 1986a; Turk et al., 2002b). The single chain of a kininogen is
folded into three family 2-cystatin-like domains, all of them being glycosylated.
In addition to the six conserved disulfide bridges, two in each domain, there are
two additional disulfides in the N-terminal region of each of the kininogen
domains 2 and 3. Kininogens are  synthesized  with a signal peptide and found
extracellularly,  with the highest concentrations, ~10 µM, in blood plasma and
synovial fluid (Abrahamson  et al., 1986; Abrahamson, 1994). There are three20
kininogen types known, H-, L- and T-kininogens. High- and low-molecular-
weight kininogens, H- and L-kininogen, respectively, are  encoded by the  same
gene (Kitamura et al., 1985) and are  identical in their N-terminal parts, but H-
kininogen is longer, containing an unrelated C-terminal region due to alternative
splicing.  T-kininogens, also called  thiostatins,  are  found only in rats (Μüller-
Esterl  et al., 1986). Kininogens are  multifunctional proteins and were  first
identified as precursors to vasoactive peptides, the kinins. The kinin sequence is
located in the C-terminal part of a kininogen, and release of the kinin fragment by
kallikrein cleavage  converts the parent H- or L-kininogen to a two-chain form,
stabilized by one interchain disulfide bond. The first domain of a kininogen is
inactive in inhibition of cysteine proteases, whereas  the two other domains can
simultaneously bind two molecules of papain-like proteases  (DeLa  Cadena &
Colman, 1991; Turk et al., 1995b, 1996a). The second  domain also inhibits
calpain (Salvesen et al., 1986).
Other cystatins and cystatin-related proteins
Many other proteins with inhibitory activity against papain-like cysteine proteases
and with sequences related to well-studied mammalian cystatins have  been
discovered.  Among them, a large  group consists of defensive  inhibitors  from
plants, phytocystatins, which have structural features  intermediate  between  those
of families 1 and 2 cystatins (Rawlings & Barrett, 1990; Brown & Dziegielewska,
1997; Margis et al., 1998). Phytocystatins also possess a specific consensus
sequence  that is absent in other cystatins. Therefore,  classification of plant
cystatins as an independent family of the cystatin superfamily has been suggested.
Cystatins from rice (Abe et al., 1988; Kondo et al., 1989, 1990, 1991), corn (Abe
et al., 1992), potato (Waldron  et al., 1993), avocado  (Kimura  et al., 1995),
papaya (Song et al., 1995), soy (Misaka et al., 1996), chelidonium majus (Rogelj
et al.,  1998),  sunflower  (Kouzuma  et al., 2001) and lima bean  (Lawrence &
Nielsen, 2001) have been described. Related inhibitors  have  also  been  found in
various lower organisms, such as African puff adder (Ritonja et al., 1987), carp
(Tsai et al., 1996), horseshoe crab (Agarwala et al., 1996), Sarcophaga peregrina
larvae (Suzuki & Natori, 1985; Saito et al., 1989), Drosophila (Delbridge &
Kelly, 1990) and nematodes (Manoury  et al., 2001; Hartmann  et al., 2002).
Cystatins in such lower organisms are more related to family 2 cystatins than the
phytocystatins are (Turk et al., 1997).
Several novel members of the cystatin superfamily have been identified on the
basis of sequences  derived  from mouse cDNA  libraries,  viz.  a  cystatin-related
epididymal and spermatogenic protein, termed Cres, and also Cres2,  Cres3,
testatin and cystatins T, TE-1 and SC (Cornwall et al., 1992; Tohonen et al.,
1998;  Kanno  et al., 1999; Shoemaker  et al., 2000; Li et al., 2002; Hsia &
Cornwall, 2003). Additionally, cDNAs and mRNAs for the human counterparts of
mouse  Cres,  Cres2  (termed  cystatin 11 in human) and testatin were  described
(Cornwall et al., 1999; Hamil et al., 2002; Wassler et al., 2002). These proteins,
specifically  expressed in the  reproductive  and  neuroendocrine  systems,  were
suggested to represent a new Cres  subgroup of cystatin family 2 (Hsia &
Cornwall, 2003; Cornwall & Hsia, 2003), as they have the conserved PW motif
but lack the two other conserved motifs. A further search of DNA databases has21
yielded a number of new Cres-like sequences in species ranging from nematode to
human (Cornwall & Hsia, 2003). The mouse Cres  protein was shown to not
inhibit the cysteine proteases papain and cathepsin B but the calcium-dependent
serine protease, prohormone convertase 2 (Cornwall et al., 2003).
A further novel human cystatin-like molecule (CLM), ubiquitously expressed in
normal tissues, has been shown to be related to cystatins C, D, S, SA and SN and
especially to mouse and human testatins (>50% similarity) (Sun et al., 2003).
However,  CLM lacks any conserved  cystatin  motifs,  and as yet no protease-
inhibitory activity has been  demonstrated for this protein. In addition, other
proteins with cystatin-related sequences but without inhibitory activity have been
identified (Brown & Dziegielewska, 1997). Among them are fetuin and histidine-
rich glycoprotein, both containing two cystatin-like domains with the conserved
disulfide bonds but lacking the conserved sequence motifs of cystatins.
Furthermore,  another  family of inactive cystatin-like proteins is represented by
mammalian cathelins, the overall fold of which is indicated to be very similar to
that of cystatins despite of a low degree of sequence identity (Kopitar et al., 1989;
Lenarcic  et al., 1993; Yang et al., 2003). Inactive  cystatin-like  proteins may
represent families that by divergence and/or gene  duplication  have  evolved  from
the archetypal cystatins.
Other protein and peptide inhibitors of cysteine proteases of the papain
family
 A number of other proteins exhibit inhibitory activity against lysosomal papain-
like  cysteine proteases. α-Macroglobulins  unspecifically trap endopeptidases of
different types, blocking the access of protein substrates to the active site of the
trapped proteinases without inactivating them (Sottrup-Jensen, 1989; Armstrong,
2001). Thyropins, which are homologous to the thyroglobulin type-1 domain, are
another  class of inhibitors  (Lenarcic & Bevec, 1998; Lenarcic & Turk, 1999).
Cathepsin L is specifically inhibited by a mammalian representative of this class,
the major histocompatibility complex (MHC) class II-associated  p41  invariant
chain fragment (Bevec et al., 1996; Guncar et al., 1999). The serpin, squamous
cell carcinoma antigen 1, has also been shown to inhibit proteases of the  papain
family  (Takeda  et al., 1995; Schick et al., 1998). Cytotoxic T-lymphocyte
antigen-2 beta (CTLA-2 beta), which is 36% identical to the proregion of mouse
cathepsin L, has been shown to inhibit cathepsin L-like proteases (Delaria et al.,
1994). CTLA-2 beta has been  suggested to represent a novel class of cysteine
protease inhibitors. In addition, peptides constituting the N-terminal  proregions
that are cleaved  off on activation of proforms of cysteine proteases may act as
potent reversible inhibitors of the mature proteases (Cygler & Mort, 1997).
Chagasin from Trypanasoma cruzi has been shown to inhibit a number of papain-
like proteases (Monteiro et al., 2001). Chagasin-like proteins were  found to be
encoded by genomes of several eukaryotes, bacteria and archaea, and thus appear to
be the first protein inhibitors of cysteine proteases  identified in prokaryotes
(Rigden et al., 2002). Chagasins are the only protease inhibitors known that adopt
an immunoglobulin-type fold (Rigden et al., 2001).22
Physiological functions of cystatins
A major role in protecting the organism against the harmful activities of cysteine
proteases, originally attributed to cystatins on the basis of their high inhibitory
potential, has been  supported by many  experimental  studies.  Colocalization of
cathepsins and cystatins as well as significantly altered  levels of the inhibitors
have thus been observed in many pathological states, including cancer, myoclonal
epilepsy, cardiovascular disease, and several autoimmune diseases, such as asthma
(Hopsu-Havu et al., 1983a, b; Lah et al., 1990; Friedrich et al., 1999; Kos et al.,
2000a, b; Cimerman et al., 2001; Locsey et al., 2001; Riccio et al., 2001; Zore et
al., 2001; Colella et al., 2002). In general, cystatin concentrations are elevated in
patients  suffering  from inflammatory diseases and autoimmunity  (reviewed in
Barrett, 1986; Hansen  et al., 2000; Mangge et al., 2000). In contrast,
development of cancer may be promoted by expression of cystatins in lower levels
or as less active isoforms (Lah et al., 1992a, b; Zore  et al., 2001; Zajc  et al.,
2002). Cystatin A was thus not detected in a number of epimeroid carcinomas and
prostate adenocarcinomas, contrary to in normal tissues (Rinne et al., 1984a, b;
Söderström et al., 1995; Mirtti et al., 2003), and cystatins B and E/M were found
to  be downregulated in prostate and esophageal carcinomas  and breast cancer,
respectively  (Sotiropoulou  et al., 1997; Shiraishi et al., 1998; Mirtti et al.,
2003). Such lower concentrations of the inhibitors of harmful cathepsins
associated with cancer progress may promote extracellular matrix distruction and
tumor invasion (Friedrich et al., 1999; Yano et al., 2001). In agreement with this
proposal, cystatin C, the most potent and abundant of human cystatins, was
shown to prevent tumor cell invasion and metastasis both in vitro  and  in  vivo
(Kolkhorst  et al., 1998; Cox et al.,  1999b).  Nevertheless,  increased  levels of
expression of cystatins by malignant cells have also been reported (Nishida et al.,
1984; Calkins & Sloane, 1995; Ebert et al., 1997; Mirtti et al., 2003;). Such
elevated extracellular levels of cystatins A, B and C in melanoma and colorectal
cancer patients strongly correlated  with  shorter  survival (Kos et al., 2000a, b).
Similarly to cancer progression, psoriasis was proposed to be associated with a
decreased inhibitory ability of cystatin A produced by epidermal cells (Ohtani et
al., 1982).
Antiviral and antibacterial activities of cystatins that could be related to the
inhibition of exogenous  proteases have also  been  demonstrated. The growth of
polio and corona virus in cultured human cells could be retarded by addition of
chicken cystatin or cystatins C or D (Korant et al., 1985; Cimerman et al., 1996;
Collins & Grubb, 1998). Moreover, peptide inhibitors with sequences mimicking
the inhibitory center of cystatin C suppressed streptococcal infections in mice and
the replication of corona and herpes simplex virus in cell cultures (Björck et al.,
1989, 1990; Kasprzykowski et al., 2000). In addition, growth of Porphyromonas
gingivalis  and  Staphylococus  aureus  was inhibited by cystatins A and S
(Takahashi et al., 1994; Naito et al., 1995), and the recently discovered cystatin
11 was similarly indicated to have antimicrobial activity against Escherichia coli
(Hamil et al., 2002). Cystatins were also found to inhibit cysteine proteases from
the  parasites  Trypanosoma  cruzi,  Trypanasoma  congolense  and  Trypanasoma
brucei brucei (Stoka et al., 1995; Troeberg  et al., 1996; Chagas et al., 1997).23
Furthermore,  phytocystatins  have been indicated to be insecticides,  inhibiting
digestive papain-like cysteine proteinases required for insect feeding and plant viral
infection (Aoki et al., 1995; Urwin et al., 1995b; Koiwa et al., 2000).
Apart from a general  protective  function,  regulatory  roles  exerted by cystatins
appear  also to be essential for normal development and functioning of the
organism in many cases. In particular, cystatin A was proposed to be involved in
differentiation of the epidermis (Rinne et al.,  1984a;  Järvinen  et al., 1987).
Similarly, cystatin B was implicated in the control of myofibril turnover in the
cytoplasm of muscle fibers (Spanier & Bird, 1982). In addition, cystatins were
suggested to participate in regulation of cell proliferation (Hiwasa et al., 1995), as
overexpression of cystatin A was found to induce increased levels of cyclin B1,
which is involved in cell-cycle regulation. Furthermore, cystatin C was shown to
be involved in local and precise balancing of the activity of testicular cathepsin L,
restricting the action of the enzyme to a specific step of spermatozoa  maturation
(Peloille  et al., 1997). A regulatory  function was also proposed for salivary
cystatins. Besides protecting periodontal tissues and presumable  exerting
antibacterial and antiviral activity (Abrahamson et al., 1997), these cystatins may
modulate the mineralization process at the saliva-enamel  interface  (Tseng  et al.,
2000).  Cres  protein was also implied to be a regulatory  protein, controlling
prohormone and proprotein processing within the reproductive and neuroendocrine
systems (Cornwall et al., 2003). Similarly, cystatin F appeared to play a role in
immune regulation through inhibition of a unique target in the hematopoietic
system (Halfon et al., 1998). Interestingly, cystatins isolated from parasites have
shown immunomodulatory activities affecting host immune systems (Manoury et
al., 2001; Vray et al., 2002). Nippocystatin secreted by an intestinal  nematode,
Nippostrongylus  brasiliensis, was thus implicated in modulation of antigen
processing in antigen-presenting cells in mice (Dainichi et al., 2001).
Furthermore, filarial nematode cystatins were  reported to be efficient in
upregulating nitric oxide production by macrophages in mice, a mediator known
to  be  an  effector  molecule against filarial worms (Hartmann  et al., 2002). In
addition, cystatins may have other functions, non-related to their cysteine-protease
inhibitory activity. Thus, carp  ovarian  cystatin was found to be important for
preventing  polyspermy in carp  eggs, acting via electrostatic  interaction as an
agglutinating factor of spermatozoa (Wang & Huang, 2002).
Certain pathological conditions are  related to congenital cystatin  mutations. A
hereditary form of human epilepsy, progressive myoclonus epilepsy (EPM1) or
Unverricht-Lundborg disease, was found to be associated with  either of several
mutations in the gene for cystatin B (Pennacchio  et al., 1996; Lalioti et al.,
1997a, b; Alakurtti et al., 2000). In addition, knock-out of the cystatin B gene in
mice resulted in development of symptoms similar to those in the human disorder
and in a broad neuronal atrophy due to apoptosis (Pennacchio  et al., 1998;
Shannon et al., 2002). A recent study provided evidence that EPM1 pathogenesis
is linked to an unbalanced cysteine protease activity due to the lack of cystatin B
inhibitory activity (Kinne et al., 2002). Significantly increased  levels of
cathepsins B, L and S activities and highly reduced levels of cystatin B mRNA
were thus detected in lymphoblastoid cells of patients suffering  from  EPM1. In
addition, a multiprotein complex of cystatin B with several non-protease proteins24
has been implicated to have a specific cerebellar function (Di Giamo et al., 2002).
Loss of this function as a consequence of the absence of cystatin B was proposed
also to contribute to EPM1 development. Another congenital defect is responsible
for hereditary cystatin C amyloid angiopathy (HCCAA). This human disease is
caused by a point mutation, Leu68 to Gln, in cystatin C, the inhibitor variant
being deposited in amyloid fibrils in the cerebral arteries. Such amyloid formation
leads to brain hemorrhage in young adults, resulting in paralysis, dementia and
eventual death (Abrahamson et al., 1992; Olafsson et al., 1996). The L68Q
mutation was found to decrease  the stability of the cystatin C molecule, this
instability  being a critical  factor  for  the development of the amyloidosis in
HCCAA patients (Gerhartz et al., 1998; Gerhartz & Abrahamson, 2002). Cystatin
C has also been shown to be colocalized with amyloid deposits in brain arterioles
in  patients with Alzheimer's disease or with  hereditary  cerebral hemorrhage
associated with amyloidosis-Dutch type (Wattendorff et al., 1982; van Duinen et
al., 1987; Vinters et al., 1990). However, the role of cystatin C in these disorders
is unknown. No mutations in the cystatin C gene in patients with Alzheimer's
disease-related  cerebral  amyloid angiopathy were  found  (Nagai  et al., 1998).
Notably, however, in the neurons most  susceptible to cell death in Alzheimer's
disease, the expression of cystatin C was elevated and cystatin C distribution was
limited and colocalized with that of cathepsin B (Deng et al., 2001).
Three-dimensional structure of cystatins and mode of inhibition of
papain-like cysteine proteases by cystatins
Overall fold of free cystatins
Three-dimensional structures of several cystatins of families 1 and 2, either free or
in complex with a target protease, have been determined by X-ray crystallography
or NMR spectrometry. The structures of free  chicken egg-white cystatin,  free
human cystatin A, human cystatin B in complex with papain and human cystatin
A in complex with cathepsin H are available to date (Bode et al., 1988; Stubbs et
al., 1990; Dieckmann et al., 1993; Martin et al., 1995; Tate et al., 1995; Craven
et al., 2000; Jenko et al., 2003;). In addition, a partially solved NMR structure of
free human cystatin C has been presented (Ekiel et al., 1997). The rather compact
globules of all these cystatins share a common global fold, consisting of an
antiparallel, five-stranded β-sheet wrapped around a central, five-turn α-helix (Fig.
4). The evolutionarily conserved sequence motifs  discussed above, which are
distant in the primary structure, are adjacent along one edge of the natively folded
molecule. The highly conserved Gly is located in an N-terminal segment that has
no direct contacts with the main body of the free cystatin. The QxVxG and LP or,
alternatively, PW regions are found in two loops connecting the second and third
β-strands and the forth and fifth β-strands, respectively. These loops in the cystatin
molecule are often referred to as the first and second hairpin loops. In most three-
dimensional  structures of cystatins, with the exception of one structure of free
cystatin A discussed later, the first hairpin loop is flanked by the N-terminal
segment and the second loop. The NMR structure of free chicken cystatin and the
most reliable NMR structure of free cystatin A (see below) have revealed that the
N-terminal  segment, at least up to the conserved  Gly, has no stable regular
conformation in solution and is highly flexible (Dieckmann et al., 1993; Martin et25
Fig. 4.  Ribbon representation of the  three-dimensional  structures of cystatin A of
family 1 and chicken egg-white cystatin of family 2. The side-chains of the  residues
conserved in the respective family are shown. The structures were drawn with the use of
the Swiss-PdbViewer program (url: http://www.expasy.ch/spdbv/) and are based on the
minimized averaged NMR structure of human cystatin A (Martin et al., 1995; PDB code
1DVC) and the X-ray crystal structure of chicken egg-white cystatin truncated by eight
residues from the N-terminus (Bode et al., 1988;  PDB code 1CEW). The two structures
are in somewhat different orientations to allow an optimal view of the side-chains.
al., 1995). Moreover, the first hairpin loops in the two structures are similar, tight
and almost rigid. The second hairpin loop of chicken cystatin is also tight, with a
well-defined conformation, but the corresponding loop in cystatin A, being two
residues longer, is wide and appreciably mobile (Dieckmann et al., 1993; Martin
et al., 1994, 1995). Another notable difference between the conformations of the
two cystatins is the longer C-terminal region of cystatin A, which runs along the
convex  face of the  β-sheet.  This C-terminal segment of eight residues is
conformationally restricted in cystatin A, although it does not adopt any regular
structure. In addition, there are minor differences in the orientation of the central
α-helices of the two cystatins, this helix in cystatin A being almost perpendicular
to the direction of the β-strands (Martin et al., 1995). These structural differences
presumably are characteristic of family 1 and 2 cystatins in general.
The X-ray structure of free chicken cystatin (Bode et al., 1988) is generally similar
to that obtained by NMR measurements (Dieckmann et al., 1993) but differs
substantially from the latter in the region comprising residues 69 to 90, which is
absent in family 1 cystatins. In the X-ray  structure,  this  region contains an
additional α-helix, whereas it is more disordered in the NMR structure (Engh et
al., 1993). This difference may be due to crystal packing effects. No evidence for
an  α-helical  conformation in the corresponding region of the related  family 2
inhibitor, human cystatin C, was obtained by NMR (Ekiel et al., 1997).
Chicken cystatin Cystatin A
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The cystatin A solution structure was originally elucidated by NMR methods by
two different groups, although with two slightly different  forms of the protein
(Martin et al., 1995; Tate et al., 1995). The two structures have the same general
fold, but the specific  conformations of several regions  differ  significantly. The
structure of authentic cystatin A, obtained at pH 5.5,  agrees  well with the
structures of free chicken cystatin and cystatin C and, in particular, with that of the
closely related cystatin B in complex with papain (Stubbs et al., 1990; Martin et
al., 1995). However, the structure of an M65L cystatin A variant lacking the N-
terminal Met, which was determined at pH 3.8,  deviates  substantially from the
other cystatin structures, in particular in the N-terminal region and the second
hairpin loop (Tate et al., 1995). However, in a recent NMR study (Craven et al.,
2000) of both wild-type cystatin A and the M65L mutant, no differences between
the structures of the two forms were found. Both structures were in accord with the
data of the first report for wild-type cystatin A (Martin et al., 1995) and with the
other cystatin structures. Moreover, the recent  investigation  demonstrated that
neither the M65L mutation and the lack of the N-terminal Met, nor the different
pH-values of the analyses, could have been responsible for the unique structural
features of ∆M/M65L-cystatin A observed by Tate et al.  (1995). Thus, the
common fold of cystatins, including the similar structure in the regions containing
the conserved sequence motifs, now appears well established.
Model of the interaction of cysteine proteases with protein inhibitors of the
cystatin superfamily
A general model for the inhibition of cysteine proteases by cystatins, often called
the "trunc model", was originally proposed on the basis of computer docking
experiments  with the structures of chicken  cystatin,  N-terminally  truncated by
eight residues, and papain solved by X-ray  crystallography  (Bode  et al.,  1988,
1990; Machleidt et al., 1989). The N-terminal region and the first and second
hairpin loops of the cystatin were seen to be arranged in a wedge that was highly
complementary to the active-site cleft of papain (Fig. 5). According to the model,
papain is inhibited by this tripartite wedge entering into the active-site cleft of the
protease, thereby preventing binding and cleavage of substrates. The interaction
was concluded to be predominantly hydrophobic, with no need for conformational
rearrangement of either of the two molecules. In the model, the two cystatin
hairpin loops ("the binding loops") made extensive interactions with papain
residues that line the wide, more open part of the active-site cleft and are relatively
remote from the catalytic Cys25. The residues in papain interacting with the two
loops  are  highly  conserved in all  related  cysteine  proteases  and  represent S'
substrate binding subsites (Fig. 1). The N-terminal segment of the cystatin was
proposed to make contacts with the residues in the narrow, bottom  part of the
papain active-site cleft. The two residues preceding the conserved  Gly in the N-
terminal region were  implicated to bind to the S2 and S3 binding subsites of
papain, although in a manner  placing  the peptide bond between  the  subsequent
pair of residues in an inappropriate position  for cleavage. Such binding in a
substrate-like manner was concluded to be possible by the N-terminal residues of
chicken  cystatin from Leu7 to Ala10 forming a tight turn, allowed by the
conserved Gly.27
Fig. 5. Stereo image demonstrating  the shape complementarity  between the inhibitory
wedge of chicken egg-white cystatin (top) and the active-site cleft of papain (bottom).
(Reprinted, with permission, from Bode et al.  (1988).  Copyright  1988,  The  EMBO
Journal.).
Although this model was proposed to be generally valid for cystatin inhibition of
target proteases, the interaction of cystatins with exopeptidases, such as cathepsins
B, H and X, would be expected to differ somewhat. The active-site cleft of these
proteases is partially blocked by either the occluding loop, the mini-chain or the
mini-loop, respectively (Musil et al., 1991; Guncar  et al., 1998; Nägler  et al.,
1999), which presumably would interfere  with cystatin binding. Docking
experiments aimed at modeling the complexes of cathepsin B with chicken
cystatin or cystatin B indeed revealed  that the second binding loop of either
inhibitor would collide with the occluding loop of the protease in the  complex
(Musil  et al., 1991). This steric hindrance  could be relieved by simultaneous
tilting and rotation of either inhibitor, although the fit achieved was not as perfect
as in the complexes with papain. In cathepsin H, the mini-chain, which restricts
substrate binding to subsites amino-terminal of the S1 pocket, was similarly
predicted to clash with the N-terminal region of cystatin B (Guncar et al., 1998).
Analogously, substrate docking experiments with the crystal structure of cathepsin
X showed that the presence of the mini-loop substantially decreases the size of the
S1' and S2' binding subsites of this protease (Nägler et al., 1999; Sivaraman et
al., 2000). The modeling suggested that the restricted S2' subsite was the main
reason for the lower inhibitory activity of cystatin C against cathepsin X than
against endopeptidases. These observations, together with the still reasonably high
affinities of cystatins for exopeptidases, indicate that cystatin binding to such
enzymes  might involve more dramatic changes in protein  structure  than the
binding to endopeptidases.  28
Three-dimensional structures and intermolecular interactions of cystatins in
complexes with target proteases
The crystal structures of complexes of a C3S variant of human cystatin B with a
carboxymethylated form of the endopeptidase, papain, and of human cystatin A
with the aminopeptidase, cathepsin H, confirm the general model of inhibition of
cysteine proteases by inhibitors of the cystatin superfamily and provide further
insight into the binding (Stubbs et al., 1990; Jenko et al., 2003). The two
structures thus verify that the complexes are  formed by insertion of the narrow
inhibitor wedge composed of the N-terminal region and the two binding loops
into the V-shaped  active-site  crevice of the  protease  (Fig. 6). Cystatin B in
complex with papain (Stubbs et al., 1990) retains the overall cystatin backbone
topology, although certain minor structural alterations are observed, especially in
the  protease  binding regions. The structure of the complex reveals ~130
intermolecular interactions <4 Å in the interface  region between  cystatin B and
papain, which are predominantly hydrophobic. A number of direct polar contacts
and possible contacts mediated via solvent molecules also contribute to the
intermolecular interaction. The N-terminal region and the first hairpin loop of the
inhibitor provide the major number of interactions with the protease, the second
binding loop being of minor importance. In addition, the C-terminal region of
cystatin B contributes further interactions with the enzyme. The N-terminal region
residues Met2–Ala5 form a rather open type II turn, which is in agreement  with
the predicted turn in the N-terminal segment of chicken cystatin in the model of
the complex with papain (Bode et al., 1988). This conformation of the N-terminal
region has not been seen in free cystatins in solution and therefore presumably is
induced by the interaction with papain. The conformation of the first binding loop
of cystatin B in the complex is very similar to that of this loop in the free
inhibitors analyzed, with the exception of the crystal structure of chicken cystatin,
possibly due to crystal contacts having influenced the latter structure (Bode et al.,
1988; Stubbs et al., 1990; Dieckmann  et al., 1993; Martin et al., 1995). The
reactive thiol group of Cys25 of papain in the complex is completely enclosed by
Ser3 and Gly4 in the N-terminal region and Gln46 and Val 47 in the first binding
loop of the inhibitor. The second  binding loop of cystatin B has a helix-like
conformation in the complex that is not found in the NMR structures of the
related cystatin A in free form. This observation indicates that this binding loop,
in addition to the N-terminal region, undergoes a certain structural adaptation to be
accommodated in the complex. The second binding loop cystatin B interacts with
the protease mainly through Leu73 and His75.
The recently  published  X-ray  structure of human cystatin A in complex with
porcine cathepsin H provides the first structural data on the binding of an
exopeptidase by a cystatin (Jenko et al., 2003). As in the complex of cystatin B
with the endopeptidase, papain, both proteins in the complex exhibit the same
overall fold as in the free state. However, the conformation of the binding sites of
the two proteins, in particular  the organization of the active-site region in
cathepsin H, are appreciably altered in the complex. Notably, the mini-chain of
cathepsin H is pushed away from its position in the free protease, as predicted by
the modeling discussed above, and the so called insertion loop of the enzyme is29
Fig. 6.  Ribbon representation of the crystal structures of the complexes between
cystatin B and papain (Stubbs et al., 1990; PDB code 1STF) and between cystatin A and
cathepsin H (Jenko et al., 2003; PDB code 1NB3). Proteases  are in black and cystatins
in grey. The view is along the protease domain interface, with the R- and L-domains at
the left and right, respectively. The structures  were drawn with the use of the Swiss-
PdbViewer program.
distorted by binding of the cystatin A N-terminal segment. The structure  further
illustrates how the flexible N-terminal segment of free cystatin A is adapted to the
presence of the cathepsin H mini-chain in the complex. The four N-terminal
residues of the inhibitor are  thus bent in a short turn, with Ile2 and Pro3
occupying the positions of two C-terminal residues of the mini chain in the free
protease. The first binding loop of cystatin A in the complex with cathepsin H has
essentially the same conformation as that of cystatin B bound to papain.
Unfortunately, however, the second binding loop of cystatin A is poorly resolved
in the structure of the complex. Remarkably, the binding loops of cystatin A are
inserted  into the cathepsin H active-site cleft up to 0.8 Å deeper  than the
corresponding loops in the cystatin B—papain complex. Moreover, there are no
water-mediated contacts in the interface between cystatin A and cathepsin H. Such
a tighter fit may be a bona-fide feature of the inhibition of papain-like proteases by
cystatins that was obscured by the carboxymethylation of papain in the previous
study (Stubbs et al., 1990).
Contributions of individual binding regions of cystatins to binding of
target proteases
Equilibrium and kinetic investigations of the inhibition of cysteine  proteases by
cystatins have provided further evidence for the validity of the docking model for
the binding proposed by Bode et al.  (1988) and have also  elucidated the
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specificity and mechanism of the interactions. Cystatins have thus been shown to
bind a number of proteases in tight equimolar complexes, often with association
rates close to those of diffusion-controlled reactions (Björk et al., 1989, 1994;
Lindahl et al., 1992a, b; Björk & Ylinenjärvi, 1990; Olsson et al., 1999; Pol &
Björk, 2003). In general,  cystatins  have been found to be rather non-specific
inhibitors that virtually distinguish only endopeptidases and exopeptidases, the
affinities of cystatins for endopeptidases being ~10
3–10
6-fold higher than those for
exopeptidases. During the last decade, the roles of the individual binding regions
of cystatins, as well as the contribution of the conserved  residues  within  these
regions, have also been extensively investigated by comparative studies of natural
inhibitors and their truncated or mutated variants.
The N-terminal region
Characterization of the binding of several plant and mammalian cysteine proteases
by the family 2 cystatins, chicken cystatin and cystatins C and D, and by their N-
terminally truncated forms has elucidated the importance of the N-terminal region
for the inhibitory function of cystatins of this family (Abrahamson et al., 1991;
Lindahl et al., 1992b; Hall et al., 1993, 1998; Björk et al., 1994). In particular,
the N-terminal segments of chicken cystatin and cystatin C have been shown to
account for ~40 % of the total free  energy of the binding of the inhibitors to
papain (Machleidt et al., 1991; Lindahl et al., 1992b; Björk et al., 1994).
However, several studies  have  revealed  that the contribution of the N-terminal
segment of cystatins to the binding varies  with the target protease. Thus,  this
region has been found to be of much lesser importance for the binding of cystatin
C to cathepsin H than to cathepsins B and L (Abrahamson et al., 1991; Hall et
al., 1995). In contrast, removal of the N-terminal segment of cystatin D abolishes
the inhibitory activity of this cystatin towards all cathepsins assayed (Hall et al.,
1998). The N-terminal segment and the remainder of the binding region of cystatin
C have been shown to contribute to the energy of binding of cysteine proteases in
a nearly additive fashion (Lindahl et al., 1992b; Björk et al., 1994; Hall et al.,
1995, 1998).
The N-terminal region of family 2 cystatins has been concluded to bind in a
substrate-like manner into the substrate-binding pockets of the cysteine proteases
studied (Grubb et al., 1990; Abrahamson et al., 1991; Hall et al., 1993; Björk et
al., 1994; Lindahl et al., 1994), in agreement  with the docking model and the
structure of the cystatin B—papain complex (Bode et al., 1988; Stubbs et al.,
1990). The two residues preceding  the  conserved  Gly of chicken  cystatin and
human cystatin C have been shown to account for the major part of the binding
energy of the entire N-terminal segment, the residue adjacent to the Gly
contributing most (Lindahl et al., 1992b; Hall et al., 1995). These two residues
are  assumed to interact with the S3 and S2 substrate-binding subsites of the
proteases, as the analogous residues of cystatin B do in the complex with papain,
and are thus termed the P3 and P2 residues of the inhibitor. In addition to provide
major binding energy, these residues have been shown also to confer  biological
selectivity to the inhibition of different endogenous cathepsins (Hall et al., 1995,
1998; Mason et al., 1998). In particular, the side chain of Leu9 of cystatin C (in
the P3 position) makes the inhibitor selective for cathepsins B and L but is31
unfavorable for binding of cathepsin H (Hall et al., 1995). Moreover, the different
P2 residues of the closely homologous cystatins C and D have been suggested to
be responsible for the different inhibitory profiles of the two cystatins (Hall et al.,
1998). In agreement with these observations, site-directed mutagenesis of the P3
and P2 residues of family 2 cystatins can alter both the inhibitory potency and the
specificity of the inhibitors (Lindahl et al., 1994; Mason et al., 1998). The P4
residue  expected to contact the putative S4 subsite is apparently of minor
importance for the binding of endopeptidases by cystatin C but may be significant
for cathepsin B inhibition (Hall et al., 1995; Cimerman et al., 1999).
In contrast to the results for family 2 cystatins, the published data on the
importance of the N-terminal region of family 1 cystatins for the inhibition of
cysteine proteases have been discrepant. Early work indicated that this region of
the family 1 cystatins is not important for the inhibition  and questioned a
substrate-like binding of the N-terminal residues of these cystatins to proteases
(Thiele et al., 1988, 1990; Machleidt et al., 1991). However, a number of later
studies provided evidence that this region plays a substantial role in the binding
(Shibuya et al., 1995a, b; Estrada et al., 1998). Moreover, in addition to Paper I
of this thesis, more recently  published work on cystatin B unequivocally
established the critical role of residues at the N-terminus of family 1 cystatins in
the high-affinity binding of cysteine proteases  (Pol & Björk, 2001, 2003). In
addition, these studies established the primary importance of the residue preceding
the conserved Gly also for family 1 cystatins. The apparent contradictions between
the results of the later and the previous investigations are  most  certainly due to
difficulties in quantifying the high affinities of cystatins for their target proteases.
Moreover, irreversible  oxidation of the P2 residue, Cys3, of cystatin B in the
earlier studies could also have caused an underestimation of the role of the N-
terminal segment of this inhibitor (Pol & Björk, 2003). Notably, a study
subsequent to Paper I found that different tripeptides at the N-terminus of cystatin
A may contribute equally well as the wild-type sequence to the  high-affinity
binding of papain (Ylinenjärvi et al., 1999).
Several investigations have focused on the role of the evolutionarily conserved Gly
in the N-terminal region of cystatins. This Gly in cystatins A and C, of families 1
and 2, as well as that in oryzacystatin-I, a plant cystatin from rice, has been
substituted by a number of bulkier residues by site-directed mutagenesis, and the
affinities and kinetics of inhibition of different cysteine proteases by the mutant
inhibitors have been studied (Hall et al., 1993; Björk et al., 1995; Shibuya et al.,
1995b; Urwin et al., 1995a; Estrada et al., 1998). In general, the affinities were
found to decrease proportionally to the size of the side chain introduced. On the
basis of these results, the conserved Gly was deduced to be a crucial residue for the
high protease-binding affinity of cystatins, functioning as a hinge that allows the
N-terminal region to adopt to the binding pockets of proteases. This conclusion is
in agreement with the conformation of the N-terminal region in the X-ray structure
of the cystatin B—papain complex. However,  the  relative importance of a high
flexibility of the N-terminal segment and of the absence of a side chain at the
position of the conserved Gly for the binding has been  shown to vary with the
protease (Estrada et al., 1998; Tseng et al., 2000). In support of the crucial role of
the evolutionarily conserved Gly4 in cystatin A, mutant forms of this inhibitor32
with high affinity for papain, obtained by random phage-display mutagenesis of
the four N-terminal residues, predominantly contained Gly in position 4
(Ylinenjärvi et al., 1999).
Comparisons of the kinetics of binding of different  cysteine  proteases by the
family 2 cystatins, chicken  cystatin and cystatin C, have  indicated  that the N-
terminal regions of these inhibitors contribute to the binding in different  ways,
depending on structure of the active-site region of the proteases  (Björk  et al.,
1994, 1995, 1996). The N-terminal  segment was found to interact with
endopeptidases at a rate apparently identical with that of the remainder of the
binding region and to be essential for stabilizing the complexes by anchoring the
protease to the inhibitor, thereby reducing the dissociation rate. In the inhibition
of the exopeptidase, cathepsin B, however, the N-terminal region was shown to
contribute to the high affinity by increasing  the  rate of association with the
protease. It was therefore  suggested that the N-terminal segment of the two
cystatins interacts with cathepsin B in an initial binding step, thereby facilitating
subsequent docking of the remaining protease  binding site into the active-site
crevice.  The N-terminal region of the cystatins might thus promote a proper
orientation of the two binding loops for  optimal  complex formation with
cathepsin B. Later work on papain, cathepsin L and cathepsin B inhibition by
Gly4-mutants of cystatin A implicated similar different  roles of the N-terminal
regions of family 1 cystatins in inhibition of endopeptidases and cathepsin B
(Estrada et al., 1998).
The first binding loop
An important role of the first binding loop of family 2 cystatins in the inhibition
of papain-like proteases appears to be well established. The first binding loop of
chicken cystatin and human cystatin C has thus been concluded to account for
~40–60% of the total energy of the binding of the inhibitors to papain and
cathepsin B (Machleidt et al., 1991; Björk et al., 1996). Moreover, a number of
equilibrium and kinetic studies with recombinant variants of cystatins have shown
the importance of residues in the conserved  QxVxG  motif in this loop for the
binding. In particular, the point mutations Q53E, Q53N and G57A, as well as
several double substitutions within the loop, in chicken cystatin led to ~10–1000-
fold reductions in the affinities for papain, actinidin and cathepsin B (Auerswald et
al., 1992). Deletion of Val55 in the first binding loop of chicken  cystatin also
resulted in a lower affinity for papain and cathepsins L and B,  and deletion of the
entire  loop in cystatin SN abolished the inhibitory activity toward papain
(Auerswald et al., 1995; Hiltke et al., 1999). Furthermore, removal of the side
chains of the first three residues in the first binding loop of cystatin SN by Gly
substitutions significantly reduced the binding affinities for papain and cathepsin
C  (Tseng  et al., 2000). Strong evidence  for  the  importance of the conserved
QVVAG  motif in the first binding loop of phytocystatins for the effective
interaction with papain has also been provided by phage display studies (Koiwa et
al., 2001). All soyacystatin variants selected to be functional in binding to papain
from a library in which the first and second binding loops were randomly mutated
thus invariantly had the QVVAG sequence in the first binding loop.  33
Interestingly, some deletions or point mutations in the first binding loop of
chicken  cystatin  were  shown to lead to a distorted binding of the N-terminal
region of the inhibitor to papain and cathepsin L, resulting in slow cleavage of the
covalent bond between Gly9 and Ala10 and release of active enzyme, so called
temporary  inhibition  (Auerswald  et al., 1995; Machleidt et al., 1995). The
appropriate sequence of the loop thus appears to be critical for optimal binding of
the cystatin N-terminal segment.
The mutations in the first binding loop of chicken cystatin predominantly affected
kdiss, indicating that this region primarily functions by stabilizing the
cystatin—protease complexes (Auerswald et al.,  1992). It is apparent, however,
that the first binding loop of family 2 cystatins contributes to varying extents to
the inhibition of different proteases (Auerswald et al., 1992, 1995; Hall et al.,
1995; Tseng et al., 2000).
In contrast to the work on family 2 cystatins, the results of similar studies of
family 1 cystatins have been inconsistent. Early work indicated the first binding
loop of cystatins A and B to be insignificant for the inhibition of papain (Nikawa
et al., 1989; Jerala et al., 1990). These results are in apparent contradiction with
the crystal structures of the complexes of cystatins A and B with cysteine
proteases that are now available, in which the first binding loop of the inhibitor is
shown to be tightly bound into the protease  active-site  crevice  (Stubbs  et al.,
1990; Jenko et al., 2003). Difficulties in measurements of very low  Kd  values
presumably are the main reason for the  underestimated role of the first binding
loop of family 1 cystatins in the early work. Moreover, the choice of substitutions
in this loop of cystatin B in one early  study  (Jerala  et al., 1990) could have
allowed intermolecular interactions similar to those in the wild-type inhibitor,
which would not have resulted in a detectable change of the affinity. In agreement
with the X-ray structures, the first binding loop of cystatin B was later implicated
to be involved in papain binding, as a V48D mutation in this loop lowered the
affinity for this enzyme by 240-fold (Machleidt et al., 1991).
The second binding loop
The importance of the second binding loop in cystatins of family 2 for the binding
of papain-like proteases has been verified in a number of studies.  Early  work
concluded  that it contributes ~13 % of the total energy of complex  formation
between chicken cystatin and papain (Machleidt et al., 1991). Moreover, deletion
of the second binding loop in chicken  cystatin was shown to result in reduced
affinities for papain and cathepsins B and L (Auerswald  et al., 1995). Several
investigations have established that the evolutionarily conserved Trp in this loop
in the family 2 cystatins is particularly important for efficient  inhibition.  Early
studies with chicken cystatin demonstrated that chemical modification of this Trp
substantially lowered the affinity for papain and also implicated a change of the
environment of the Trp on binding of proteases, indicating that this residue is
involved in the interaction (Lindahl et al., 1988; Nycander & Björk, 1990).
Further work showed that removal of the side chain of Trp106 in the loop in
human cystatin C by a Gly substitution dramatically  decreased  the affinities for
papain, actinidin and cathepsins B and H, whereas the affinities for cathepsins L34
and S were only moderately reduced (Hall et al., 1995; Björk et al., 1996; Mason
et al., 1998). However, replacement of Trp106 by Phe reduced  the affinity to a
lower extent than the Gly replacement, implying that the hydrophobic side chain
of Phe can partly compensate for that of Trp in protease  binding (Björk et al.,
1996). On the basis of these studies, it was concluded that Trp106 in the second
binding loop of cystatin C accounts for ~20–30% of the energy of binding of the
inhibitor to papain, actinidin and cathepsins B and H (Björk et al., 1996). A
subsequent investigation  demonstrated  that  substitution of both residues of the
conserved PW motif in the second binding loop of human salivary cystatin SN
with a GG segment appreciably reduced cathepsin C inhibition, although no effect
on papain inhibition  was noticed (Tseng  et al., 2000). The significance of the
conserved Trp in the second binding loop of phytocystatins for protease binding
has also been shown by phage display selection of variants with high affinity for
papain from the soyacystatin library with the two binding loops randomly mutated
(Koiwa et al., 2001). All selected  variants  thus had Trp in the second  binding
loop,  whereas  other residues, both hydrophobic and basic, were  found N-
terminally of this Trp.
The importance of the second binding loop of a family 1 cystatin, cystatin B, in
the inhibition of different cysteine proteases has been shown in one study (Pol &
Björk, 1999). Leu73 and His75 of this loop were demonstrated to be important for
high-affinity  binding of papain and cathepsins B and H, Leu73 being most
essential. The two residues together were concluded to contribute similarly as the
Trp in the second binding loop of cystatin C to papain and cathepsin H binding,
i.e. ~20–30% of the total binding energy.
Kinetic studies of cysteine protease  inhibition by natural and mutant forms of
cystatins have revealed that the second binding loop of the inhibitors is primarily
essential for the stabilization of the complexes with the proteases by maintaining a
low kdiss (Björk et al., 1996; Pol & Björk, 1999). However, varying contributions
of the loop to the binding have been observed for different proteases, presumably
reflecting a diversity of structures of and around the active-site clefts of the
enzymes (Auerswald et al., 1995; Hall et al., 1995; Björk et al., 1996; Mason et
al., 1998; Pol & Björk, 1999; Tseng et al., 2000).
The C-terminal region
As mentioned earlier, cystatins of family 1 have a nine-residue long  C-terminal
extension, compared with cystatins of family 2 (Bode et al., 1988). The X-ray
structure of the complex between cystatin B and papain indicated the C-terminal
region of this inhibitor to be involved in interactions with the L-domain of the
protease (Stubbs et al., 1990). One residue of this region, Tyr97, was deduced to
contribute to stabilization of the complex by an extensive net of close (<4 Å),
predominantly hydrophobic, contacts with papain (Stubbs et al., 1990). Despite
this observation, binding of papain by cystatin B was initially reported not to be
affected by truncation of 11 C-terminal residues of the inhibitor (Jerala  et al.,
1991). In contrast, in a more recent study, site-directed mutagenesis of Tyr97 to
Ala verified the importance of this  residue for tight  anchoring of cystatin B to
papain and also, although to a lesser extent, to cathepsins L and H (Pol & Björk,35
1999). Tyr97 of cystatin B was shown to contribute ~6–12% to the total energy of
binding to these proteases but to be of no importance for cathepsin B inhibition
(Pol & Björk, 1999).
Tyr97 is not well conserved in family 1 cystatins, being replaced by Gly in the
related inhibitor,  cystatin A. Moreover, the crystal structure of the complex of
cystatin A with cathepsin H suggests that the C-terminal end of the inhibitor is
not essential for  binding to this protease  (Jenko  et al., 2003). It is therefore
uncertain whether the C-terminal end of cystatin A is of any functional
importance. Unfortunately, no experimental studies on the role of the C-terminal
region of other family 1 inhibitors than cystatin B in the binding of cysteine
proteases have been reported.
The legumain-binding region
Several  family 2 cystatins inhibit  mammalian legumain, as mentioned above.
Lysosomal  cysteine  proteases of the papain and legumain families are
evolutionarily unrelated, having different folds and active-site motifs (Chen et al.,
1998). The legumain binding site of cystatins with ability to bind this protease
has been found to be located on the side of the cystatin molecule directly opposite
to the wedge-shaped  binding site for papain-like proteases. As a consequence,
these cystatins are able to form ternary complexes containing one molecule of each
of the two types of cysteine proteases (Alvarez-Fernandez et al., 1999). The highly
conserved Asn39 (in cystatin C numbering), located in the loop  connecting the
central α-helix with the first long strand of the β-sheet of the cystatin, was shown
to  be a key residue for legumain inhibitory function. In addition, a proper
conformation of this loop was suggested to be necessary  for  the  inhibition
(Alvarez-Fernandez et al., 1999). Family 1 cystatins A and B, in which this loop
is two residues shorter, as well as cystatin D of family 2, which has a one-residue
insertion in the loop, thus do not show legumain inhibitory activity. Presumably,
other regions of a cystatin capable of binding legumain are  also involved in
interaction with the enzyme (Alvarez-Fernandez et al., 1999).
Kinetic mechanism of the interaction between cystatins and their target
proteases
Binding of cystatins to target endopeptidases that have an open active-site cleft,
such as papain and cathepsin L, occurs  with  rate  constants  approaching  those
expected for diffusion-limited reactions, which implies that there is no need for a
global conformational adjustment of either of the interacting proteins on complex
formation (Björk et al., 1989, 1994; Björk & Ylinenjärvi, 1990; Lindahl et al.,
1992a, b; Turk et al., 1994; Olsson et al., 1999; Pol & Björk, 2003). Moreover,
a simple, one-step mechanism of the interaction of cystatins with such proteases
has  been  indicated by stopped-flow kinetics studies of the binding at high
inhibitor concentrations (Björk et al., 1989; Björk & Ylinenjärvi, 1990; Lindahl
et al., 1992b; Turk et al., 1994; Pol et al., 1995). These  observations are in
agreement with the docking model for complex formation based on the crystal
structures of chicken cystatin and papain that was discussed earlier (Bode  et al.,
1988).  However,  more  refined  rapid kinetics analyses of papain binding to36
cystatin A  with  its  N-terminus labeled  with a fluorescent  group  have  strongly
implicated a two-step mechanism of the cystatin—papain interaction, with an
independent binding of the N-terminal region of the inhibitor subsequent to that of
the two binding loops (Estrada et al., 2000). The rates of these two binding steps
were  concluded to be undistinguishable in conventional studies of the binding
kinetics, accounting for the apparent  one-step reaction observed in such studies
(Estrada et al., 2000).
The presence of the occluding loop on top of the cathepsin B active-site cleft was
proposed to be responsible for the generally lower affinities of cystatins  for  this
exopeptidase,  compared  with those for endopeptidases with open active  sites
(Musil et al., 1991; Henskens et al., 1996). The interference of the occluding loop
with the interaction between  the cystatin binding wedge  and the cathepsin B
active-site cleft, predicted by the computer docking experiments (see above), was
confirmed by site-directed mutagenesis. An engineered  partial deletion of the
occluding loop of cathepsin B thus resulted in >40-fold higher affinity for cystatin
C (Illy et al., 1997). The occlusion of part of the substrate binding site by the
loop results in a mechanism of cystatin binding to cathepsin B deviating from that
of the binding to  endopeptidases. As discussed above, the N-terminal region of
cystatins was shown to be essential for a high rate of association of the inhibitors
with cathepsin B, in contrast to the binding to endopeptidases. Furthermore, kobs
derived from stopped-flow kinetics analyses of the interaction of cystatin C with
recombinant cathepsin B was shown to depend hyperbolically on inhibitor
concentration (Nycander et al., 1998). This behavior is compatible with a two-step
interaction, with a conformational change in one or both proteins in the second,
rate-limiting step (Fersht, 1985). On the basis of these results, Nycander  et al.
(1998) suggested that the N-terminal region of cystatin C interacts rapidly with the
protease in the first step of the reaction, followed by a slower displacement of the
cathepsin B occluding loop by the remainder of the binding region of cystatin C
entering the active-site cleft of the enzyme.37
Present investigation
Before  this investigation was started, the general features of the binding and
inhibition of papain-like cysteine proteases by family 2 cystatins had been well
established. In particular, several studies had elucidated the critical roles of three
binding regions of these cystatins, viz. the N-terminal region and the first and
second  hairpin  loops, in the inhibition. The importance and roles of the
corresponding structural elements in cystatins of family 1 had not been studied as
extensively and, moreover, discrepant data concerning  these aspects had been
reported. Thus, further work was required to clarify whether the main features of
cystatin inhibition of target proteases are general for different cystatin families. To
this end, the bulk of the work in this investigation was done with the family 1
cystatin, cystatin A. A major aim was to elucidate  the  specific  roles of the N-
terminal region and the second binding loop of cystatin A in the binding to
different cysteine proteases (Papers I and II). Gaining a deeper understanding of the
complicated mode of inhibition of cathepsin B,  one of the most  abundant
mammalian proteases, by cystatins was another goal of this study (Papers III and
IV). The relationship between  the inhibitory abilities of cystatins and the
structures of their individual binding regions was a further important aspect of the
investigation (especially Paper IV).
Contribution of cystatin A N-terminal residues to the
inhibition of different cysteine proteases (Paper I)
Previous investigations had indicated the importance of the N-terminal region of
the family 1 cystatin, cystatin A, for the high affinity of this inhibitor for target
proteases (Takeda et al., 1985; Pol et al., 1995; Shibuya et al., 1995a, b; Estrada
et al., 1998;). However,  much of the data reported  was uncertain due to
experimental problems  (see  below) and concerned  only  papain  inhibition.  Only
one study had unequivocally verified  the  importance of the evolutionarily
conserved Gly4 to the binding of cystatin A to different target proteases (Estrada et
al., 1998). The work in Paper I elucidated the role of the flexible cystatin A N-
terminal segment in the inhibition by characterizing the contribution of the first
three  N-terminal residues to the binding to papain, as well as to the more
physiologically relevant proteases, cathepsins L and B.  Three cystatin A mutants,
lacking either one, two or three  residues  from the N-terminus (∆M-, ∆MI- and
∆MIP-cystatin A, respectively), were obtained by recombinant protein technology,
and their inhibitory properties were examined by equilibrium and kinetic methods.
Far-UV circular dichroism  spectra of the  three  mutants did not indicate any
conformational changes in cystatin A due to the deletions at the N-terminus. This
finding was consistent with previous NMR studies of cystatin A that had revealed
a high flexibility of the first five residues of the protein and a lack of interactions
between these residues and the rest of the polypeptide chain (Martin et al., 1995).
Hence,  deletions within  this flexible segment would be expected to have no
influence on the conformation of the rest of cystatin molecule. Therefore, any
decreased affinity of the truncated forms of cystatin A for proteases  should  well38
reflect the loss of the contributions of the corresponding N-terminal residues to the
binding.
Sequential deletion of the three residues at the N-terminus led, in general, to a
progressive decrease of cystatin A affinity for all three proteases studied, but the
extent of this reduction  varied  substantially with the protease. The removal of
Met1 had a minimal effect on the affinities for papain and cathepsin B, as well as
on the corresponding binding kinetics. The truncation by two residues, Met1 and
Ile2, resulted in the affinities for papain and cathepsin B being decreased by 900-
and 200-fold, respectively. Unfortunately, however, less precise information could
be obtained for cathepsin L. Since only upper limits of Kd of ∆M- and wild-type
cystatin A for this enzyme could be estimated, only the smallest possible increase
in  Kd, ~3-fold, caused by the truncation of the two initial residues, could be
deduced. Despite these uncertainties, the deletion of the two initial  residues
appeared to affect cystatin A affinity for cathepsin L to a lesser extent than the
affinity for the other proteases. Removal also of Pro3 had a major effect on the
inhibition of all proteases studied. Kd increased by 2×106, ≥7×104- and 7×104-
fold for papain, cathepsin L and cathepsin B, respectively, in comparison with that
of the wild-type inhibitor. This indicates that the MIP-segment is responsible for
~40% of the total  free  energy of binding of cystatin A to the proteases. This
contribution to cathepsin B binding is appreciably  higher than that of the
corresponding,  although five to seven residues longer, N-terminal regions of
family 2 cystatins. However, the N-terminal segments of cystatin A and family 2
cystatins contribute similarly to papain binding (Björk et al., 1994). As has been
reported for family 2 cystatins, the two residues of cystatin A preceding the
evolutionaryly conserved Gly4, i.e. Ile2 and Pro3, in particular  the latter, were
thus found to contribute most of the N-terminal region to the binding energy. In
some aspects, however, the results of the present work were discrepant with those
reported earlier for cystatin A (Shibuya et al., 1995a). In the previous work, the
binding of cystatin A to papain was not affected by N-terminal truncations of the
residues preceding Pro3, and the affinity of ∆MIPG-cystatin A was only ~200-fold
lower  than that of the control variant (Shibuya et al., 1995a). The apparent
contradiction of these results with those of Paper I is most  probably due to the
inappropriate experimental approach used in the previous studies for measuring
very low Kd values (Shibuya et al., 1995a). Therefore, the conclusions regarding
the role of residues in the N-terminal region of cystatin A in the binding to target
proteases made in these studies on the basis of uncertain values of Kd are doubtful.
Analyses of the binding kinetics revealed  different  mechanisms behind the
reduction in affinity for different  proteases.  The  decreased  affinities of the N-
terminally truncated cystatin A variants for the two proteases with an open active-
site cleft (papain and cathepsin L) were entirely due to increases in kdiss. A similar
behavior had been previously observed for the binding of N-terminally truncated
cystatins of family 2 (Björk et al., 1994). These findings led to the suggestion
that in the case of papain and cathepsin L, a cystatin A—protease  complex is
initially  formed  with  unobstructed  binding of the more rigid first and second
binding loops into the open active-site cleft of these proteases. The flexible N-
terminal segment may then bind in a second step and stabilize the complex. When
this work was undertaken, no direct evidence in proof of such a two-step binding39
of cystatins to proteases with an open active site was available (Björk et al., 1989,
1990; Lindahl et al., 1992b; Turk et al., 1994; Pol et al., 1995) but such
evidence was obtained in later work (Estrada  et al.,  2000). In Paper I, the N-
terminal segment of cystatin A was proposed to bind to papain and cathepsin L in
a substrate-like manner, with Ile2 and Pro3 contacting the S3 and S2 protease
binding subsites, respectively (Stubbs et al., 1990; Lindahl et al., 1994; Hall et
al., 1995, 1998; Mason et al., 1998).
By contrast, in the case of cathepsin B, in which the catalytic site is obstructed by
an occluding loop, both kass and kdiss, in particular the former, were affected by the
truncations. This observation indicated a mechanism of cathepsin B binding
different from that of binding of proteases with an exposed active site. A previous
study had demonstrated that cystatin C, of family 2, binds to cathepsin B in a
two-step reaction and had indicated that the second step involves displacement of
the occluding loop of cathepsin B to allow formation of a final, tight bimolecular
complex (Nycander et al., 1998). On the basis of these previous findings and the
results of Paper I, it was suggested that cystatin A also binds to cathepsin B in an
analogous two-step reaction. The flexible N-terminal segment of cystatin A was
assumed to bind to this protease in the first step, thereby  facilitating the
subsequent displacement of the occluding loop in the second step (Björk et al.,
1994, 1995, 1996).
It should be added that the importance of the N-terminal residues of another family
1 cystatin, cystatin B, for the inhibition of a number of cysteine proteases has also
been demonstrated later (Pol & Björk, 2001, 2003). The major proposals made in
Paper I regarding the role of the flexible N-terminal segment of family 1 cystatins
in the binding to different target proteases were verified for cystatin B and have
been further corroborated in subsequent investigations (Estrada et al., 2000; Pol &
Björk, 2001, 2003; Paper IV).
Importance of the second binding loop of cystatin A for
stabilization of the complexes with different target proteases
(Paper II)
Several  studies had indicated an essential role of the second binding loop of
cystatin B of family 1 and of cystatin C and chicken  cystatin of family 2 in
inhibition of papain-like cysteine proteases before this work was started (Nycander
& Björk, 1990; Auerswald et al., 1995; Björk et al., 1996; Pol & Björk, 1999).
However, certain structural peculiarities of the  corresponding  loop in cystatin A
cast some doubts on the importance of this loop for tight binding of this inhibitor
to target proteases. The loop in cystatin A thus lacks not only the Trp that is
essential for the inhibition by family 2 cystatins but also the important His in
cystatin B. In the X-ray crystal structure of the complex between cystatin B and
papain, His75 in the second binding loop of the inhibitor accounts for a number of
close contacts with  papain (Stubbs et al., 1990). Moreover, an important role of
His75 in stabilizing complexes of cystatin B with different cysteine proteases has
also  been  unambiguously  demonstrated by mutagenesis experiments (Pol &
Björk, 1999). However, in cystatin A this His is replaced by Gly. This40
substitution would be expected to lead to loss of the contacts with the protease
donated by the side chain of His75 in the cystatin B complex and, consequently,
to  a  decreased  contribution of the second binding loop of cystatin A to the
binding. Furthermore, the high flexibility of this loop in cystatin A (Martin et al.,
1995) could either be detrimental to the binding or, conversely, promote the
binding by allowing an orientation of the loop that is beneficial for the interaction
with target proteases. These uncertainties concerning the role of the cystatin A
second binding loop prompted the examination in Paper II of the contribution of
side chains of individual residues within the most flexible part of the loop to the
binding of different cysteine proteases. Four residues of the loop, Leu73, Pro74,
Gln76, and Asn77 were  concluded to be likely  candidates  contributing to the
intermolecular interaction. Therefore,  four recombinant cystatin A variants, each
having a single residue within the loop substituted with Gly, were constructed by
site-directed mutagenesis. The binding of the L73G-, P74G-, Q76G-, and N77G-
cystatin A variants to papain, cathepsin L and cathepsin B was then studied by
equilibrium and kinetic methods. The contribution of the remaining residue of the
loop, Gly75, could not be investigated by the approach taken in this work.
Only  replacement of Leu73, highly conserved in family 1 cystatins, with Gly
affected  the affinity of cystatin A for the proteases  studied to any appreciable
extent. The increase in Kd for papain and cathepsin B was ~320- and ~4000-fold,
respectively. The other three mutations did not have  any  significant  effect on
cystatin A binding to papain and cathepsin B, with the exception of the P74G
mutation, which resulted in Kd for the complex with cathepsin B being increased
by ~10-fold. Unfortunately, the effects of the mutations could not be properly
quantified in the case of cathepsin L, for which only a lower limit of the decrease
in  affinity due to the L73G mutation of ~10-fold could be estimated. No
indications of any significant change in the affinity for this protease were observed
on introduction of the three other mutations in cystatin A. The losses in binding
affinity indicate that the side chain of Leu73 is responsible for ~18 and ~34% of
the total unitary free  energy change for binding of cystatin A to papain and
cathepsin B, respectively. This contribution of Leu73 of cystatin A to the free
energy of binding to papain is similar to that of Leu73 in the second binding loop
of cystatin B (Pol & Björk, 1999) and to that of essential Trp106 in the second
hairpin loop of cystatin C of family 2 (Björk et al., 1996). However, in the case
of cathepsin B inhibition, the contribution of Leu73 is substantially higher than
that of Trp106 of cystatin C (Björk et al., 1996). Together, Leu73 and Pro74
account for ~45% of the total energy of binding of cystatin A to the latter protease.
In contrast to these two residues, Gln76 and Asn77 contribute negligibly to the
binding of either enzyme. Taken together, the results manifest the importance of
the second binding loop of cystatin A for the inhibition of different cysteine
proteases, although the contributions of this loop vary  with the protease, being
especially pronounced for cathepsin B. It is noteworthy that the flexible N-
terminal segment and the second binding loop of cystatin A together contribute
almost 90% of the energy of binding of this protein inhibitor to cathepsin B,
whereas the joint contribution of the corresponding regions of cystatin C appears
to be appreciably smaller (Björk et al., 1994, 1996; Paper I). This  observation41
implies that the first binding loop of cystatin A contributes appreciably  less to
cathepsin B binding than the corresponding loop of cystatin C.
Analysis of the binding kinetics revealed that kass was unaffected by the mutations
and that the decreased affinities were exclusively due to an increased kdiss.  These
results indicate that the role of the second binding loop of cystatin A is to
stabilize the complex between cystatin A and its target  protease after this complex
has already been formed. Hence, the role of this loop of cystatin A is the same as
that of the corresponding loops of cystatins B and C (Björk et al., 1996; Pol &
Björk, 1999). Leu73 presumably keeps  cystatin A attached to the  proteases by
directly interacting with the latter. Pro74 could contribute to stabilizing the
complex with cathepsin B either by direct hydrophobic contacts with the enzyme
or, alternatively, by maintaining Leu73 in an orientation beneficial for its
interaction with the protease.
To provide further  insight into the structural  implications of these results, a
computer model of the complex between human cystatin A and papain was built
on the basis of the X-ray crystal structure of human C3S-cystatin B in complex
with S-(carboxymethyl)papain (Stubbs et al., 1990). The cystatin A polypeptide
chain could be accommodated  within the main-chain coordinates of cystatin B
without any sterical  problems in the region of the second binding loop. The
computer modeling largely corroborated the results of the experimental work. In
the model of the complex, Leu73 of cystatin A thus exhibited six close
hydrophobic contacts (within 4Å) with Trp177, highly conserved in papain-like
cysteine proteases. Such interactions were  experimentally  supported by
fluorescence difference spectra implying that the environment of Trp177 is less
hydrophobic in the complex with L73G-cystatin A, i.e. in the absence of the
Leu73 side chain, than in the complex with the wild-type inhibitor. The model
indicated  only a small contribution of Pro74 to stabilization of the cystatin
A—papain complex. In complete agreement with the experimental data, no close
intermolecular  interactions of Gln76 and Asn77 with  papain  were  seen in the
modeled complex.
Evidence for dislocation of the occluding loop of cathepsin B in
the second step of the binding by cystatins (Paper III)
Cathepsin B differs from other members of the papain family, such as papain and
cathepsin L, by the presence of an occluding loop (residues 108–119) that partially
blocks one end of the substrate binding cleft. In the X-ray structure of cathepsin B,
this loop is stabilized by a number of interactions, including two salt bridges,
between His110 and Asp22 and between Arg116 and Asp224 (Musil et al., 1991).
Earlier work had demonstrated that the occluding loop normally restricts the access
of cystatins to the active site but is a mobile element and may move, e.g. when an
endopeptidase substrate binds to cathepsin B (Musil et al., 1991; Cygler et al.,
1996; Turk et al., 1996b; Illy et al., 1997; Nägler et al., 1997). Previous to the
studies in Paper III, a complex, two-step mechanism of cathepsin B binding by
cystatin C had been  revealed by stopped-flow kinetic studies (Nycander  et al.,
1998). The second step of the interaction, involving a conformational change, had42
been interpreted to be due to displacement of the occluding loop by cystatin C
(Nycander et al., 1998).
The aim of this work was to investigate whether this two-step mode of binding to
cathepsin B is general for different cystatins and to provide unequivocal evidence
for dislocation of the occluding loop on formation of the tight complex in the
second step. To this end, the salt bridge between His110 and Asp22 of the enzyme
was disrupted by mutating His110 to Ala. This mutation had been shown
previously to increase  the mobility of the loop (Nägler  et al., 1997) and,
consequently, would be expected to relieve the  interference of the loop with
cystatin binding. Since a H110A mutant of active cathepsin B was found to be
unstable due to autoproteolysis, an additional C29A mutation that rendered
cathepsin B enzymatically inactive was also introduced, the resulting
H110A/C29A-cathepsin B double mutant being used in this study. This
construction necessitated control experiments with C29A-cathepsin B, lacking the
catalytic cysteine. Stopped-flow kinetics analyses of the binding of cystatins A
and C, of families 1 and 2, to C29A- and H110A/C29A-cathepsin B at high
inhibitor  concentrations  were  monitored by changes of intrinsic  fluorescence
accompanying complex formation.
For the binding of either cystatin C or A to the C29A-cathepsin B control, the
progress  curves  were  exponential and the dependence of kobs  on inhibitor
concentration was hyperbolic. This behavior is indicative of a two-step reaction
with a conformational change in the second step for both cystatins. The simplest
kinetic mechanism compatible with the data (Fersht, 1985) involves the formation
of a weak, initial complex (PI in the scheme below) in the first step of the binding
reaction. This complex is assumed to be in a fast equilibrium with free  protease
and inhibitor (P and I, respectively). The first step is followed by a reversible
conformational change leading to formation of a final, tight complex (PI*) in the
second step:
     Kd k+2
P + I ⇔ PI ⇔ PI*
                 k-2           
In this mechanism, K1  is the dissociation equilibrium constant of the initial
complex and k+2 and k-2 are the forward and reverse rate constants of the second,
rate-limiting step. K1 and k+2 were obtained by fitting the hyperbolic dependence
of  kobs vs  inhibitor  concentration to the equation for the proposed mechanism
(Fersht, 1985). The overall association rate constant, kass, was determined from the
initial slope of the hyperbolic dependence as k+2/K1,  whereas  the  overall
dissociation rate constant, kdiss, which is identical to k-2 in this mechanism, was
measured by displacement experiments.
The C29A mutation in cathepsin B was found not to alter the major characteristics
of the two-step binding of wild-type cathepsin B by cystatin C. A corresponding
comparison was not possible in the case of cystatin A, as the stopped-flow
kinetics of cystatin A binding to wild-type cathepsin B could not be quantified
due to a low fluorescence change accompanying  the  binding and a pronounced
photodecomposition.  Nevertheless,  comparison  with the results of inhibition43
kinetics, monitored by the loss of enzyme  activity,  for wild-type cathepsin B
showed that the C29A mutation only moderately affected the overall rate constants
of cystatin A binding. Taken together, the results indicate that C29A-cathepsin B
is a satisfactory model for characterizing  the mechanism of cystatin binding to
wild-type cathepsin B. The studies strongly support the contention that cystatin A
binds to wild-type cathepsin B in the same manner as to C29A-cathepsin B and
similar to the manner in which cystatin C binds to the two enzyme  forms.
Therefore, the two-step mechanism of binding to cathepsin B discussed above was
suggested to be common for all cystatins.
For both cystatin C and A binding to H110A/C29A-cathepsin B, the dependence
of  kobs  on inhibitor concentration was linear up to ~80–100 µM,  these
concentration limits being determined by the amounts of inhibitor available. This
behavior is characteristic of a one-step reaction. However, another alternative that
is consistent with the results is that both K1  and  k+2  for the binding of both
inhibitors  were  increased  substantially by the H110A mutation, and the data
obtained corresponded to the initial, approximately linear segments of hyperbolic
concentration dependencies. Simulations indicated that in this case K1 must have
increased >>2–3-fold for both inhibitors and k+2 must have increased >>2-fold for
cystatin C and >>10-fold for cystatin A. Both  alternative  explanations  clearly
demonstrate  that disruption of the salt bridge between  His110 and Asp22 in
cathepsin B, leading to an increased  mobility of the occluding loop, causes a
striking change in the kinetics of cystatin binding. They also strongly support the
proposal that the second step of cystatin binding to wild-type cathepsin B
involves displacement of the occluding loop. It is possible that the loop no longer
occludes the S' subsites in H110A/C29A-cathepsin B, which is consistent with
cystatins binding to this cathepsin B variant in the same one-step manner as to
target proteases with an exposed active  site.  Alternatively, the loop could have
become sufficiently mobile in H110A/C29A-cathepsin B to be easily displaced by
cystatins in a two-step reaction. In this case, dislocation of the occluding loop in
the second binding step was presumably promoted by an initial weak interaction
of either cystatin with the cathepsin B mutant, most likely mediated by the N-
terminal regions of the inhibitors, as proposed for the binding to wild-type
cathepsin B (Björk et al., 1996; Paper I).
The analyses of the rapid kinetics of binding of cystatins A and C to C29A-
cathepsin B provided further  insight into the differences  between  the inhibitory
properties of the two inhibitors against cathepsin B. They revealed that the forward
rate  constant of the dislocation of the occluding loop of the enzyme, k+2, is
markedly lower for cystatin A than for cystatin C. Cystatin A is thus much less
effective than cystatin C in displacing the occluding loop in the second step. This
low rate of loop dislocation is the main reason for the considerably lower overall
rate  constant of cathepsin B inhibition by cystatin A, compared  with that for
inhibition by cystatin C.44
Improvement of the inhibitory characteristics of cystatin A by
grafting of the protease binding regions of more potent
inhibitors (Paper IV)
This investigation was inspired by the results of the previous work in Paper III. In
particular, this work had shown that cystatin A is considerably less effective than
cystatin C in displacing the occluding loop of cathepsin B in the second step of
complex formation, which accounts for the slow  overall  rate of inhibition of
cathepsin B by cystatin A. The latter inhibitor also binds other papain-like
cysteine proteases less tightly than cystatin C. The present  study was therefore
undertaken to identify the structural features of cystatin C that make it a better
displacer of the occluding loop of cathepsin B and also a stronger inhibitor of
other cysteine proteases. To this end, the influence  of introducing individual
binding regions of cystatin C onto the framework of cystatin A on the affinities
and kinetics of the binding to papain and cathepsin B was investigated in this
work.
Cystatin A variants in which either the N-terminal segment preceding the
conserved Gly or the first or second binding loops were  made identical with or
similar to the corresponding regions of cystatin C (Fig. 3) were obtained by site-
directed  mutagenesis. In two N-terminal region mutants,  N(1–10)CC- and
N(8–10)-CC-cystatin A, the authentic N-terminal segment, MIP, was replaced by
cystatin C residues 1–10 or 8–10. In V47I-cystatin A, the first binding loop was
made identical with that of cystatin C by a single point mutation, Val47 to Ile. In
G75W-cystatin A, the PW motif, highly conserved in the second binding loop of
family 2 cystatins, was introduced into the corresponding loop of cystatin A. In
addition, in G75H-cystatin A the second  binding  loop,  which is the binding
region of cystatin A differing mostly from those in cystatin B, was engineered to
be similar to that of the latter inhibitor by a Gly75 to His substitution.
The affinities of N(1–10)CC- and N(8–10)CC-cystatin A for cathepsin B were
higher, by ~15- and >3-fold,  respectively, than that of the wild-type inhibitor,
predominantly due to an increased kass. As a consequence, the affinities of the N-
terminal cystatin A mutants for cathepsin B exceeded those of any natural cystatin
known. To elucidate the reason for the higher kass, the stopped-flow kinetics of
binding of the N(1–10)CC mutant to an inactive form of cathepsin B,  in which
the catalytic Cys was substituted by Ala, were  analyzed at high inhibitor
concentrations. In previous work (Paper III), the C29A mutation had been shown
not to affect the mechanism and kinetics of cathepsin B binding by cystatins. As
in the case of wild-type cystatin A in the earlier work, kobs for the N(1–10)CC-
cystatin A association with C29A-cathepsin B showed a hyperbolic dependence on
the inhibitor concentration. This behavior is characteristic for a two-step  binding
mechanism with a conformational change occurring in the second, rate-limiting
step (see Scheme in Paper III). The N-terminal substitution thus did not change
the mechanism of cathepsin B binding. However, it markedly affected the rate of
the second step of the interaction, the forward rate constant for this step, k+2,
being increased by ~100-fold, approaching that of cystatin C binding. Therefore,
the results indicated that the N-terminal segment of cystatin C in the chimeric
inhibitor, and presumably also in intact cystatin C, contributes to increasing the45
rate of cathepsin B binding by efficiently  promoting the displacement of the
occluding loop of cathepsin B in the second binding step,  presumably by
appropriately orienting the two binding loops. Nevertheless, the cystatin A mutant
harboring the entire N-terminal segment of cystatin C did not attain the full rate of
cystatin C association with cathepsin B, possibly due to other residues of the N-
terminal region, C-terminal of the conserved Gly, being of importance in cystatin
C.
Both mutations in the second binding loop favorably affected both kass and kdiss of
papain binding by cystatin A, which resulted in ~10-fold higher affinities of these
two mutants than of the wild-type inhibitor for papain. The G75H mutation
predominantly decreased the  rate of dissociation of the complexes with papain,
whereas the G75W mutation mainly accelerated complex formation. Presumably,
both mutations caused local conformational changes in the second binding loop of
cystatin A, which is highly flexible in the solution structure of the free wild-type
inhibitor  (Martin et al., 1995). This restriction in flexibility could promote a
faster association with papain. Moreover, computer modeling indicated that the
His or Trp introduced into the loop could contribute to an increased stabilization
of the complexes with papain by direct interactions with residues of the protease
active-site cleft.
In contrast to these results, grafting of the N-terminal residues of cystatin C onto
the cystatin A scaffold  did not improve papain inhibition. Similarly, the
mutations in the second  binding loop of cystatin A that introduced essential
residues of cystatins C and B did not enhance the inhibition of cathepsin B. None
of these mutations appreciably influenced either the affinities or the kinetics of
binding of the corresponding protease, with the exception of the G75W mutation.
The Trp side chain apparently disturbed the accommodation of the second binding
loop of G75W-cystatin A into the active-site crevice of cathepsin B, leading to a
6-fold increase in kdiss. Grafting of the first binding loop of cystatin C onto the
cystatin A framework did not improve the inhibitory characteristics of cystatin A
for either papain or cathepsin B. Instead, the affinities of this  chimeric  inhibitor
for the two enzymes  were  ~2–5-fold lower than those of wild-type cystatin A,
exclusively due to a higher kdiss. The bulkier Ile replacing Val47 in the first
binding loop of the cystatin A mutant therefore must disturb the binding of either
this loop or the N-terminal segment of the inhibitor to the enzymes (Stubbs et al.,
1990). Presumably, the presence of Ile in the corresponding position in the first
binding loop of cystatin C also contributes to the lower stability of the complex
of this inhibitor with cathepsin B, compared with that of cystatin A.
The results of this study outline a strategy for engineering of new specific and
highly potent inhibitors of different cysteine proteases, endopeptidases as well as
exopeptidases. Such small protein inhibitors may be potentially useful for
abolishing the harmful activities of cathepsins that are  related to many
pathophysiological disorders.46
General conclusions
This investigation has primarily elucidated the mechanism of inhibition of papain-
like cysteine proteases by human cystatin A. Overall, the studies performed give
evidence  demonstrating that cystatin A, a representative of family 1 cystatins,
interacts  with  target  proteases in a similar  manner as family 2 cystatins. The
contributions of individual residues of the N-terminal region and the second
binding loop of cystatin A to the inhibition of different  cysteine  proteases  have
been evaluated. These data, together with analyses of the binding kinetics, give
insight into the background for the high affinity of cystatin A—cysteine protease
interactions. Moreover, successful attempts at improving the inhibitory capacity of
cystatin A by protein engineering have been made. The results indicate possible
approaches for the design of effective inhibitors of the harmful activity of cysteine
proteases in pathological conditions. The principal findings of the study are as
follows:
•  The flexible N-terminal segment of cystatin A is indispensable for the high
affinity of this inhibitor for papain, cathepsin L and cathepsin B. Three
residues at the N-terminus together account for ~40% of the total free energy
of cystatin A binding to these proteases. Met1 is of minimal importance,
whereas Pro3, preceding the evolutionary conserved Gly4, is responsible for
most of the contribution of the N-terminal segment to the binding. In the case
of the inhibition of proteases  with an easily accessible active site, such as
papain and cathepsin L, the primary role of the N-terminal segment is to
stabilize the cystatin A—protease complex after this complex has already been
formed. The flexible N-terminal segment of cystatin A most likely binds to
such proteases after the remainder of the inhibitory wedge. In the binding of
cathepsin B, in which an occluding loop blocks the active site, the N-terminal
segment is essential for fast association of cystatin A with the protease,
although it also participates in stabilization of the bimolecular complex. The
N-terminal segment of cystatin A most likely interacts  with  cathepsin B in
the first step of a two-step binding reaction.
•  The second binding loop of cystatin A is highly important for  efficient
inhibition of different cysteine proteases. The most flexible segment of this
loop,  comprising the residues from Leu73 to Asn77, contributes ~20 and
~45% of the energy of binding of cystatin A to papain and cathepsin B,
respectively. The contribution of the loop to protease binding is due almost
solely to Leu73, highly conserved in family 1 cystatins. This residue
presumably establishes direct hydrophobic interactions with the target
protease. Pro74 is also of appreciable importance for cathepsin B binding, in
which this residue may either form direct contacts with the protease or assist
by positioning Leu73 for appropriate interaction. The second binding loop of
cystatin A participates in the inhibition of cysteine proteases by serving as an
anchor, stabilizing the bimolecular complex once it is formed.
•  Cystatins A and C bind to an inactive form of cathepsin B, in which the
catalytic  Cys29 is replaced by Ala, by a two-step mechanism, with a
conformational  change in the second, rate-limiting step. Strong evidence47
indicates that cystatin A, like cystatin C, interacts with wild-type cathepsin B
in the same manner. Increasing the mobility of the occluding loop of C29A-
cathepsin B by disruption of a salt bridge between  His110 in the loop and
Asn22 of the main body of the protein by a H110A mutation causes a marked
change in the mode of binding of both cystatins A and C, transforming it into
an apparent one-step reaction. Thus, the conformational change in the second
step of cathepsin B binding by cystatins most  certainly  involves the
occluding loop being dislocated by the cystatin to allow formation of a tight
complex. Cystatin A is less efficient  than cystatin C in displacing the
occluding loop. The lower overall rate of association of cystatin A than of
cystatin C with cathepsin B is primarily a consequence of this slow
displacement of the occluding loop of the enzyme in the second binding step.
•  Essential inhibitory properties of the most potent mammalian inhibitor of
papain-like proteases, cystatin C, can be imparted onto the weaker inhibitor,
cystatin A. Replacement of the three residues preceding the conserved Gly in
the N-terminal region of cystatin A by the corresponding ten residue long N-
terminal segment of cystatin C results in affinities for cathepsin B exceeding
that of any natural cystatin known. The high affinity is due to the cystatin
A/C chimera binding to cathepsin B appreciably faster than cystatin A but
retaining the low kdiss characteristic for the interaction of cystatin A with this
protease. The N-terminal segment of cystatin C on the cystatin A framework
markedly increases the rate of dislocation of the occluding loop of the inactive
C29A-cathepsin B variant in the second step of complex formation, the rate
constant of this step being comparable with that for the binding by cystatin
C. This region of cystatin C is thus strongly indicated to be pivotal for the
better ability of this inhibitor than of cystatin A to displace the occluding
loop of cathepsin B and thus for the higher overall association rate. By
contrast, grafting the N-terminal residues of cystatin C onto the cystatin A
scaffold does not appreciably enhance the inhibition of papain. Mutations of
Gly75 to Trp or His, which increase  the  sequence  similarity of the second
binding loop of cystatin A with those in cystatins C and B, respectively,
significantly enhance the affinity for papain up to a level similar to that of
cystatin C by favorably affecting both  kass  and  kdiss.  These  mutations,
however, are  somewhat deleterious for cathepsin B binding by cystatin A.
Introduction of the first binding loop of cystatin C onto the cystatin A
framework  does not improve the inhibitory characteristics of cystatin A
against either papain or cathepsin B. Taken together, the results show that the
inhibitory  efficiency of cystatins  can be substantially improved by protein
engineering.48
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